{"gene":"FOXD1","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":2003,"finding":"FoxD1 (BF-2) directly binds to a conserved HNF3β site in the Placental Growth Factor (PlGF) promoter and activates its transcription; PlGF is absent in BF-2 null kidney stroma, and exogenous PlGF stimulates ureteric bud branching in vitro, establishing PlGF as a direct, physiologically relevant transcriptional target of FoxD1 in renal stromal cells.","method":"Inducible FoxD1 expression + microarray, promoter binding assay, BF-2 null mouse, in vitro kidney organ culture","journal":"Current biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (microarray, promoter binding, null mouse, organ culture) in one rigorous study establishing direct transcriptional regulation and physiological relevance","pmids":["13678594"],"is_preprint":false},{"year":1999,"finding":"The FOXD1 (FREAC-4) promoter is regulated by the transcription factor Ets-1; three Ets-1 cis-elements within the first 152 nucleotides upstream of the transcription start site mediate ~6-fold induction, and overexpression of Ets-1 in HEK293 cells is sufficient to increase FREAC-4 mRNA levels.","method":"Transfection reporter assay, DNase I in vitro protection (footprinting) with recombinant Ets-1, site-directed mutagenesis of Ets-1 binding sites, mRNA quantification","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro footprinting with recombinant protein plus mutagenesis and cell transfection, single lab but multiple orthogonal methods","pmids":["9867825"],"is_preprint":false},{"year":1996,"finding":"The FOXD1 (FREAC-4) promoter contains regulatory elements responsive to WT-1 (3-fold induction) and mutant p53 (7-fold induction), while wild-type p53 represses it ~4-fold; a deletion series identified a fragment necessary for WT-1 inducibility that contains at least one WT-1 cis-element.","method":"Promoter-luciferase reporter cotransfection in kidney-derived cell lines (293, COS-7), promoter deletion series, RNase protection assay for transcription start site","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean reporter + deletion mapping in relevant cell lines, single lab, no in vitro protein binding confirmed","pmids":["8702877"],"is_preprint":false},{"year":2002,"finding":"FOXD1 activates the RI-alpha subunit of cAMP-dependent PKA via the 1b promoter in Sertoli cells through sequences downstream of the transcription start site; protein kinase B alpha/Akt1 strongly potentiates this effect, and an inactive FOXD1 mutant reduces cAMP-mediated induction of the RI-alpha 1b reporter, placing FOXD1 as an integrator of PKB and cAMP hormonal signals.","method":"Promoter deletion mapping, bandshift assay (EMSA), cotransfection reporter assays in 3T3-L1 adipocytes and Sertoli cells, dominant-negative FOXD1 mutant","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — deletion mapping, EMSA, cotransfection with mutant construct, two cell types, multiple orthogonal approaches in one study","pmids":["11943768"],"is_preprint":false},{"year":2004,"finding":"Foxd1 is required in ventrotemporal (VT) retina for specification of the ipsilateral retinal projection: Foxd1-null mice lose Zic2 and EphB1 expression in VT retina, the Foxg1 domain expands, and VT RGC axons fail to be repulsed by chiasm cells in co-culture, aberrantly projecting contralaterally. Foxd1 also patterns the ventral diencephalon where the optic chiasm forms.","method":"Foxd1 knockout mouse, immunostaining, retina-chiasm co-culture repulsion assay, in vivo axon tracing","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function mouse with multiple molecular readouts and functional co-culture assay, replicated across several experimental approaches","pmids":["15509772"],"is_preprint":false},{"year":2006,"finding":"Foxd1 coordinates suppression of both NF-AT and NF-κB pathways in T cells: Foxd1 deficiency results in increased NF-AT activity correlated with reduced casein kinase 1 (an NF-AT inhibitory kinase), and increased NF-κB activity correlated with reduced Foxj1 (which regulates IκBβ). Foxd1-null mice develop multiorgan systemic inflammation and exaggerated Th-cell cytokine production.","method":"Foxd1 knockout mouse, T cell functional assays (cytokine production, MLR proliferation), NF-AT and NF-κB activity assays, epistasis analysis with casein kinase 1 and Foxj1","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO with defined cellular phenotype and pathway placement, single lab, multiple pathway readouts","pmids":["16585573"],"is_preprint":false},{"year":2009,"finding":"In the developing chick retina, FoxD1 (CBF2) acts as a transcriptional repressor to establish temporal retinal identity: misexpression of FoxD1 represses FoxG1, GH6, SOHo1, and ephrin-A5, and induces EphA3. Chimeric mutant studies showed FoxD1 functions through its repressor domain. FGF and Wnt signaling induce region-specific FoxD1 expression in the optic vesicle.","method":"In ovo electroporation (gain-of-function), chimeric FoxD1 repressor/activator domain mutants, immunostaining in chick","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — chimeric domain-swap mutagenesis combined with in vivo misexpression, identifies mechanism (transcriptional repression) and downstream targets","pmids":["19450575"],"is_preprint":false},{"year":2011,"finding":"In mouse, Foxd1 is necessary for temporal retinal identity and ipsilateral axonal projection; EphA6 is identified as a downstream effector of Foxd1 that directs temporal axons to the rostral colliculus.","method":"Foxd1 conditional mouse genetics, axon tracing, immunostaining for EphA6 and retinal identity markers","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss-of-function mouse with defined molecular target (EphA6) and functional axon-projection phenotype","pmids":["21490208"],"is_preprint":false},{"year":2013,"finding":"FOXD1 represses the gene encoding decorin (DCN) in cortical interstitial cells of the embryonic kidney; in Foxd1-null mice DCN is de-repressed and antagonizes BMP/SMAD signaling required for nephron progenitor cell differentiation. Compound genetic inactivation of Dcn partially rescues the nephron progenitor differentiation defect in Foxd1 null kidneys.","method":"Foxd1 knockout mouse, target gene screening, compound Foxd1/Dcn double knockout, BMP/SMAD signaling analysis","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double knockout rescue plus molecular pathway analysis, multiple methods in one rigorous study","pmids":["24284212"],"is_preprint":false},{"year":2014,"finding":"Foxd1 is required as a mediator of cell reprogramming to iPSCs: knockout of Foxd1 inhibits downstream transcriptional events including Dax1 expression (a component of the pluripotency autoregulatory network), and fate-mapping shows >95% of iPSC colonies derive from transiently Foxd1-positive cells at a mid-stage of reprogramming.","method":"Foxd1 knockout, shRNA knockdown, fate-mapping with Foxd1-reporter, transcriptome analysis during reprogramming","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — KO with defined transcriptional phenotype (Dax1) plus fate-mapping, multiple orthogonal methods","pmids":["24496101"],"is_preprint":false},{"year":2014,"finding":"FOXD1 promotes breast cancer cell proliferation and chemoresistance by inducing G1-to-S phase transition through targeting p27 expression (decreasing p27 levels).","method":"shRNA knockdown and overexpression in breast cancer cell lines, cell cycle analysis, p27 western blot","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — KD/OE with defined phenotype and molecular target, single lab, no ChIP or direct promoter assay reported in abstract","pmids":["25462566"],"is_preprint":false},{"year":2016,"finding":"FOXD1 is expressed predominantly in mesenchymal (MES) glioma stem cells and regulates the transcriptional activity of ALDH1A3, an established marker of MES GSCs; shRNA attenuation of FOXD1 abolishes MES GSC clonogenicity in vitro and in vivo.","method":"shRNA, in vitro sphere/clonogenicity assay, in vivo xenograft, transcriptional reporter for ALDH1A3, Drosophila RNAi epistasis","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (shRNA, in vivo xenograft, transcriptional assay, cross-species RNAi epistasis) in one study","pmids":["27569208"],"is_preprint":false},{"year":2016,"finding":"Renal interstitial cells with EPO-producing capacity are entirely derived from FOXD1-expressing stroma; PHD2 inactivation alone in FOXD1-lineage cells induces renal Epo in a limited number of interstitial cells, and additional heterozygous deficiency for PHD1 and PHD3 increases the EPO-producing cell fraction, placing PHD/HIF-2 regulation of EPO production within the FOXD1 stromal lineage.","method":"Conditional Cre/lox knockout (Foxd1-Cre), EPO reporter fate mapping, pharmacological PHD inhibition, genetic PHD compound mutants","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — lineage-specific conditional genetics with multiple PHD allele combinations and pharmacological validation","pmids":["27088801"],"is_preprint":false},{"year":2017,"finding":"Foxd1 is an upstream positive regulator of the renin-angiotensin system (RAS) during metanephric kidney development: Foxd1-null embryonic kidneys show decreased renin, AGT, ACE, and AT1R expression, and overexpression of Foxd1 in mesenchymal MK4 cells increases these RAS components in vitro.","method":"Foxd1 knockout mouse, qRT-PCR, western blot, immunohistochemistry, Foxd1 overexpression in MK4 cells, ex vivo ureteric bud branching assay","journal":"Pediatric research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse combined with gain-of-function cell experiment, multiple RAS targets assessed, single lab","pmids":["28665931"],"is_preprint":false},{"year":2017,"finding":"FOXD1 is transcriptionally regulated by canonical Sonic Hedgehog (Shh) signaling; Foxd1 is required downstream of Shh for the proliferative response — Foxd1 deletion abrogates SHH-induced proliferation, whereas FOXD1 overexpression alone is sufficient to induce proliferation. FOXD1 reduces reporter activity of a Fox enhancer in the second intron of Cdkn1c (p57), and Shh pathway activation of Foxd1 is followed by Cdkn1c downregulation, defining a Shh-Foxd1-Cdkn1c mitogenic circuit.","method":"Mouse embryonic fibroblasts, Foxd1 knockout, FOXD1 overexpression, CDK inhibitor pharmacology, luciferase reporter for Cdkn1c Fox enhancer, cranial neural crest cell experiments","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — KO plus OE with pharmacological rescue, direct promoter reporter assay, multiple cell contexts, single lab","pmids":["29284139"],"is_preprint":false},{"year":2018,"finding":"FOXD1 directly represses MICU1 expression in embryonic stem/progenitor cells, leading to suppressed mitochondrial Ca2+ uptake; experimental restoration of MICU1 in hESCs/hiPSCs re-established periodic cytosolic Ca2+ oscillations and promoted cellular differentiation and maturation.","method":"hESC/hiPSC and neonatal myocyte models, MICU1 expression analysis, FOXD1 overexpression/knockdown, Ca2+ imaging, bioenergetics assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct repression established by gain/loss-of-function with defined molecular target (MICU1) and functional consequence (Ca2+ dynamics, differentiation), multiple cell models","pmids":["30158529"],"is_preprint":false},{"year":2018,"finding":"In developing hypothalamus, Foxd1 acts in neuroepithelial/neural progenitor cells to allow sustained expression of molecular markers of the suprachiasmatic, paraventricular, and periventricular hypothalamic nuclei; Foxd1-deficient mice show progressive loss of these markers after neurogenesis is complete, indicating Foxd1 is required for terminal differentiation of anterior hypothalamic neuronal subtypes.","method":"Foxd1 knockout mouse, immunostaining, in situ hybridization for hypothalamic markers (Six3, Vax1, neuropeptides)","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KO with spatiotemporally defined molecular phenotype, single lab","pmids":["29679559"],"is_preprint":false},{"year":2018,"finding":"In Xenopus, FoxD1 acts downstream of BMP antagonism to induce dorsal mesoderm (muscle and notochord) and is sensitive to local Wnt and BMP signaling; in the presence of Wnt or BMP activity FoxD1 induces posterior neural tissue, but when BMP and Wnt are repressed it induces anterior neural tissue, demonstrating context-dependent transcription factor activity.","method":"Antisense morpholino knockdown in Xenopus laevis, misexpression, epistasis with Wnt and BMP pathway manipulations","journal":"The International journal of developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — morpholino KD with epistasis, multiple signaling contexts tested, single lab, Xenopus model","pmids":["28621426"],"is_preprint":false},{"year":2018,"finding":"FOXD1 transactivates galectin-3 (Gal-3) by directly binding to the Gal-3 promoter in lung cancer cells; ERK1/2 interacts with FOXD1 in the cytosol and translocates it into the nucleus to activate Gal-3. Gal-3 in turn upregulates FOXD1 via ETS-1/integrin-β1 signaling, forming a positive regulatory feedback loop that promotes lung cancer aggressiveness.","method":"Microarray, FOXD1 OE/KD in lung cancer cells, ChIP (FOXD1 binding to Gal-3 promoter), co-immunoprecipitation (ERK1/2-FOXD1), rescue experiments, xenograft","journal":"Cancers","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP plus Co-IP plus functional rescue with multiple orthogonal methods in one study","pmids":["31795213"],"is_preprint":false},{"year":2018,"finding":"FOXD1 suppresses proliferation of ovarian cancer cells and induces G1 arrest in a p53-independent manner by promoting p21 expression; chromatin immunoprecipitation and dual-luciferase reporter assays established FOXD1 as a direct transcriptional activator of p21.","method":"Lentiviral FOXD1 expression, ChIP, dual-luciferase reporter assay, flow cytometry, xenograft","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay establish direct transcriptional regulation of p21, single lab","pmids":["29620165"],"is_preprint":false},{"year":2018,"finding":"FOXD1 promotes melanoma invasion and migration via indirect regulation of RAC1B (a tumor-specific Rac1 isoform) and MMP9; knockdown of RAC1B abrogates the enhanced invasiveness induced by FOXD1 overexpression, and FOXD1 regulates RAC1B through alternative splicing.","method":"FOXD1 KD/OE in melanoma cells, gene expression profiling, functional invasion/migration assays in vitro and in vivo, RAC1B rescue experiments","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — KD/OE with rescue, gene expression profiling, identified pathway (RAC1B alternative splicing), single lab","pmids":["30110134"],"is_preprint":false},{"year":2019,"finding":"YAP cooperates with TEAD to activate transcription of FOXD1; CRISPR/Cas9 KO of YAP in hMSCs reduces FOXD1 expression and causes premature cellular senescence, whereas overexpression of either YAP or FOXD1 rejuvenates aged hMSCs, establishing a YAP-TEAD-FOXD1 axis that controls senescence.","method":"CRISPR/Cas9 KO, lentiviral overexpression, ChIP (YAP/TEAD binding), senescence assays, intra-articular lentiviral delivery in mouse OA model","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO plus ChIP plus in vivo rescue, multiple orthogonal methods establishing direct transcriptional regulation","pmids":["30933975"],"is_preprint":false},{"year":2019,"finding":"CXCL5 promotes angiogenesis via CXCR2-dependent activation of the AKT/NF-κB pathway, which upregulates FOXD1, which in turn drives VEGF-A expression; silencing FOXD1 attenuates HUVEC tube formation, proliferation, and migration stimulated by rhCXCL5.","method":"shFOXD1/shCXCR2 lentiviral stable knockdown in HUVECs, tube formation assay, AKT/NF-κB pathway inhibitors, in vivo Matrigel plug, xenograft","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — stable KD with pharmacological pathway inhibition and in vivo validation, single lab","pmids":["30792394"],"is_preprint":false},{"year":2019,"finding":"miR-92a-1-5p targets FOXD1 (and FOXJ1) to activate CDX2 and downstream intestinal markers in bile-acids-induced gastric intestinal metaplasia via the NF-κB pathway; bile acids upregulate miR-92a-1-5p, suppressing FOXD1 and activating the miR-92a-1-5p/FOXD1/NF-κB/CDX2 axis.","method":"miRNA/mRNA microarray, miRNA mimic/inhibitor transfection, luciferase reporter assay (miR-92a-1-5p → FOXD1 3'-UTR), immunohistochemistry in IM tissue microarrays","journal":"Gut","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter plus functional cell assays with clinical tissue validation, single lab","pmids":["30635407"],"is_preprint":false},{"year":2020,"finding":"FOXD1 directly promotes SLC2A1 (GLUT1) transcription and also inhibits GLUT1 mRNA degradation through the RNA-induced silencing complex, thereby enhancing aerobic glycolysis and promoting pancreatic cancer cell proliferation, invasion, and metastasis.","method":"FOXD1 OE/KD in pancreatic cancer cells, luciferase reporter (SLC2A1 promoter), RISC assay, in vitro and in vivo functional assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dual mechanism (transcription + RISC) established by reporter and RISC assays, single lab","pmids":["36057597"],"is_preprint":false},{"year":2020,"finding":"FOXD1 repression in oral cancer cells downregulates G3BP2 (a negative regulator of p53), as determined by luciferase-based promoter assay establishing G3BP2 as a direct FOXD1 transcriptional target; FOXD1 KD promotes TXNIP expression (downstream of IFN signaling and a p53 activator) and enhances radiosensitivity.","method":"FOXD1 KD, differential gene expression analysis, luciferase promoter reporter assay for G3BP2, GSEA, luciferase reporter for IFN/p53 pathways","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter reporter establishes G3BP2 as FOXD1 target, single lab","pmids":["32967107"],"is_preprint":false},{"year":2020,"finding":"METTL3 (m6A methyltransferase) mediates m6A modification of foxd1 mRNA; foxd1 mRNA levels and its methylation levels are elevated in renal ischemia-reperfusion injury and hypoxia/reoxygenation models, and METTL3 inhibition reduces both m6A and foxd1 mRNA, decreasing apoptosis.","method":"MeRIP sequencing, MeRIP-qRT-PCR, METTL3 inhibition in NRK-52E cells, rat IRI model","journal":"American journal of physiology. Renal physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MeRIP-seq identifies m6A modification of foxd1 mRNA by METTL3 with functional inhibition validation, single lab","pmids":["32954854"],"is_preprint":false},{"year":2021,"finding":"FOXD1 directly binds to the SNAI2 promoter and activates its transcription, thereby promoting EMT and cell stemness in oral squamous cell carcinoma; elevated SNAI2 mediates the downstream effects on EMT markers and sphere formation.","method":"ChIP (FOXD1 binding to SNAI2 promoter), luciferase reporter assay, FOXD1 KD/OE, in vivo xenograft","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay establish direct transcriptional regulation of SNAI2, single lab","pmids":["34348789"],"is_preprint":false},{"year":2021,"finding":"FOXD1 regulates the cell cycle in clear cell renal cell carcinoma (ccRCC) by controlling histone H3 phosphorylation at the G2/M transition; FOXD1 knockout in 786-O cells causes extended G2/M phase, deficient phospho-histone H3, increased DNA damage, and reduced tumor formation in xenografts, with downstream MICU1 as a co-regulated metabolic target.","method":"CRISPR/Cas9 FOXD1 knockout in 786-O cells, flow cytometry cell cycle analysis, immunoblotting for phospho-H3, γH2AX/TUNEL for DNA damage, Seahorse metabolic assay, xenograft","journal":"BMC cancer","confidence":"High","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with multiple orthogonal functional readouts (cell cycle, histone phosphorylation, DNA damage, metabolism, in vivo), single lab","pmids":["33761914"],"is_preprint":false},{"year":2022,"finding":"USP21 is a deubiquitinase for FOXD1 in mesenchymal glioblastoma stem cells: USP21 directly interacts with FOXD1 and reverses its K48-linked polyubiquitination, preventing proteasomal degradation. USP21 silencing enhances FOXD1 polyubiquitination and degradation, attenuating MES identity, effects rescued by FOXD1 reintroduction.","method":"Co-immunoprecipitation, ubiquitination assay (K48 linkage), USP21 knockdown with FOXD1 rescue, disulfiram (USP21 inhibitor) in vivo GBM xenograft","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP plus ubiquitination assay plus genetic rescue plus in vivo pharmacology, multiple orthogonal methods establishing the deubiquitinase–substrate relationship","pmids":["35974001"],"is_preprint":false},{"year":2022,"finding":"FOXD1 promotes CTC formation and breast cancer metastasis by directly inducing RalA expression (binding to the RalA promoter via ChIP-seq/CUT&Tag-seq); RalA then forms a complex with ANXA2 and Src, promoting ANXA2 Tyr23 phosphorylation and ERK1/2 activation.","method":"ChIP-seq, CUT&Tag-seq, luciferase reporter, GST-pulldown, co-immunoprecipitation, phosphorylation assays, in vitro and in vivo CTC/metastasis models, ERK1/2 inhibitor treatment","journal":"Journal of experimental & clinical cancer research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP-seq plus CUT&Tag plus pulldown plus Co-IP plus in vivo rescue, multiple orthogonal methods establishing direct target and complex","pmids":["36229838"],"is_preprint":false},{"year":2022,"finding":"In Sertoli cells, FOXD1 regulates testis development and function: FOXD1 knockdown in chicken Sertoli cells decreases AMH, SOX9, and RIα (PKA regulatory subunit) expression and increases androgen receptor expression, with DMRT1 unchanged, placing FOXD1 upstream of SOX9 in the Sertoli cell gene program.","method":"RNA interference in chicken Sertoli cells, qRT-PCR, immunohistochemistry, immunofluorescence for cell-type markers","journal":"Reproduction, fertility, and development","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — RNAi with multiple molecular readouts in primary cells, single lab, avian model","pmids":["30641031"],"is_preprint":false},{"year":2022,"finding":"FOXD1 directly binds to the CTGF promoter and activates its transcription in melanoma cells, promoting dedifferentiation and resistance to BRAF inhibitor vemurafenib; CTGF knockdown increases BRAFi sensitivity similarly to FOXD1 KD, and recombinant CTGF restores resistance to FOXD1-KD cells.","method":"ChIP, luciferase reporter assay, FOXD1 KD/OE, CTGF KD, recombinant CTGF rescue, vemurafenib sensitivity assays","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter plus rescue experiments, single lab","pmids":["33837564"],"is_preprint":false},{"year":2023,"finding":"FOXD1 directly interacts with β-catenin and promotes its nuclear translocation, activating downstream Wnt target genes (LGR5, Sox2), thereby increasing CRC cell stemness and chemoresistance; the β-catenin inhibitor XAV-939 blocks FOXD1-driven stemness.","method":"Co-immunoprecipitation (FOXD1–β-catenin), β-catenin nuclear fractionation, XAV-939 pharmacological rescue, stemness assays, xenograft limiting dilution","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP establishing direct interaction, nuclear fractionation, pharmacological rescue, single lab","pmids":["37203394"],"is_preprint":false},{"year":2023,"finding":"FOXD1 binds to the p21 promoter and inhibits its transcription, thereby blocking the CDK2/Rb signaling pathway and preventing senescence while accelerating proliferation of HNSCC cells; miR-30e-5p suppresses FOXD1 translation by targeting its 3'-UTR.","method":"ChIP (FOXD1 binding to p21 promoter), luciferase reporter, CDK2 inhibitor rescue, FOXD1 KD/OE, flow cytometry for senescence, miRNA target validation","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter plus CDK2 inhibitor rescue, single lab","pmids":["37563111"],"is_preprint":false},{"year":2023,"finding":"TRIM21 mediates K48-linked polyubiquitination of FOXD1 in hyperglycaemic conditions, leading to its proteasomal degradation; reduced FOXD1 decreases BCL-2 transcription (FOXD1 is a direct transcriptional activator of BCL-2), driving apoptosis in retinal and renal tissues. Tartary buckwheat flavonoids reverse FOXD1 protein downregulation.","method":"Ubiquitination assay (K48-linkage), proteasome inhibition, FOXD1 promoter reporter for BCL-2, FOXD1 KD/OE, diabetic mouse model tissue analysis","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ubiquitination assay plus reporter assay plus in vivo model, single lab","pmids":["38092733"],"is_preprint":false},{"year":2023,"finding":"FOXD1 promotes vasculogenic mimicry in glioma via transcriptional activation of DKK1 (direct promoter activation confirmed); upstream, SUMOylated RALY (facilitated by UBA2) increases FOXD1 mRNA stability.","method":"FOXD1 promoter-luciferase assay for DKK1, SUMOylation assay (SUMO1 conjugation), RALY stability assay, FOXD1 KD, in vivo glioma xenograft","journal":"Cell biology and toxicology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter for DKK1 plus SUMOylation assay, single lab","pmids":["37906341"],"is_preprint":false},{"year":2024,"finding":"FOXD1 directly binds to the KIFC1 promoter and activates its transcription (ChIP and dual-luciferase), upregulating the glycolysis pathway and conferring cisplatin resistance in breast cancer cells; FOXD1 positively regulates ANXA4 expression via KIFC1.","method":"ChIP, dual-luciferase reporter assay, FOXD1 OE/KD, KIFC1 KD/OE, ECAR/OCR metabolic assays, in vivo xenograft","journal":"Reproductive biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay plus metabolic assays, single lab","pmids":["39541848"],"is_preprint":false},{"year":2025,"finding":"FOXD1 directly regulates IL-6 transcription in melanoma cells; FOXD1-induced IL-6 is pivotal for MDSC induction and immunosuppressive microenvironment formation. Blocking IL-6 reverses MDSC-associated immunosuppression driven by FOXD1 overexpression. In vivo, FOXD1-OE tumors contained more PD-L1+ MDSCs.","method":"FOXD1 OE/KD in melanoma cells, IL-6 ELISA, MDSC functional assay (arginase activity, T-cell suppression), IL-6 neutralization, flow cytometry, in vivo xenograft","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional rescue with IL-6 blockade plus in vivo validation, single lab, mechanism of IL-6 as direct transcriptional target suggested but full ChIP data not explicitly described in abstract","pmids":["40210238"],"is_preprint":false},{"year":2025,"finding":"NAT10 stabilizes FOXD1 mRNA through ac4C (N4-acetylcytidine) modification; FOXD1 in turn acts as a transcriptional activator of NAT10 in NPC cells (confirmed by ChIP and luciferase assay), forming a positive feedback loop that drives NPC progression.","method":"RIP, mRNA stability assay, ChIP (FOXD1 binding to NAT10 promoter), luciferase reporter, FOXD1/NAT10 KD/OE, xenograft","journal":"Hereditas","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter plus RIP-mRNA stability, multiple orthogonal methods, single lab","pmids":["40999468"],"is_preprint":false},{"year":2025,"finding":"ALG3 directly interacts with FOXD1 and induces N-glycosylation at Asn176, which increases FOXD1 protein stability and promotes its nuclear localization; nuclear FOXD1 then transcriptionally activates BNIP3 to promote mitophagy and gemcitabine resistance in NPC cells.","method":"Co-IP (ALG3–FOXD1 interaction), N-glycosylation site mapping (Asn176), nuclear fractionation, ChIP/luciferase for BNIP3 promoter, mitophagy assay, drug resistance assay, xenograft","journal":"International journal of biological sciences","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — Co-IP plus PTM site identification plus nuclear localization plus direct promoter assay plus in vivo, multiple orthogonal methods, single lab","pmids":["40083705"],"is_preprint":false},{"year":2019,"finding":"FOXD1 mutations (p.His267Tyr and p.Arg57del) lead to disturbances in FOXD1 transcriptional activity on the C3 and PlGF gene promoters, functionally linking FOXD1 to RPL, RIF, IUGR, and preeclampsia pathogenesis via regulation of implantation/placental genes.","method":"FOXD1 gene sequencing in patients, in vitro gene reporter assays with mutant FOXD1 constructs on C3 and PlGF promoters","journal":"Molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay with patient-derived mutants directly tests transcriptional activity, single lab","pmids":["31395028"],"is_preprint":false},{"year":2016,"finding":"FOXD1 sequence variants identified in RSA patients lead to perturbations in FOXD1 transactivation properties on promoters of implantation/placentation genes in vitro, implicating FOXD1 functional mutations in mammalian implantation processes.","method":"FOXD1 sequencing in RSA patients and controls, in vitro reporter transactivation assays with FOXD1 mutant constructs","journal":"Open biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay with disease-associated mutants, single lab","pmids":["27805902"],"is_preprint":false},{"year":2025,"finding":"FOXD1 directly represses B4GALNT2 transcription in colorectal cancer cells; deletion experiments of putative FOXD1 binding sites in the ~2800 bp upstream B4GALNT2 promoter-luciferase construct confirmed regulatory binding, and FOXD1 knockdown in SW948 cells stimulates B4GALNT2 expression.","method":"Luciferase reporter with FOXD1 binding site deletions, transient transfection, FOXD1 KD","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — deletion reporter assay plus KD validation, single lab","pmids":["39805916"],"is_preprint":false},{"year":2025,"finding":"FOXD1 directly activates ANXA3 transcription by binding to its promoter (validated by dual-luciferase reporter and ChIP), promoting ANXA4 expression via ANXA3–ANXA4 protein interaction (co-IP), thereby conferring cisplatin resistance in lung cancer cells.","method":"ChIP, dual-luciferase reporter (FOXD1 binding to ANXA3 promoter), co-IP (ANXA3–ANXA4), immunofluorescence, FOXD1/ANXA3 KD rescue experiments, xenograft","journal":"Naunyn-Schmiedeberg's archives of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter plus Co-IP, single lab","pmids":["40095055"],"is_preprint":false}],"current_model":"FOXD1 is a forkhead/winged-helix transcription factor that functions primarily as a context-dependent transcriptional activator or repressor of a broad set of target genes (including PlGF, ALDH1A3, MICU1, SNAI2, Gal-3, RalA, GLUT1/SLC2A1, BCL-2, p21, BNIP3, KIFC1, DKK1, G3BP2, ANXA3, NAT10, and decorin/DCN); its activity is regulated upstream by YAP-TEAD, Sonic Hedgehog-GLI, Ets-1, WT-1/p53, and AKT/PKB signaling, and its protein stability is controlled post-translationally by TRIM21-mediated K48-polyubiquitination (counteracted by the deubiquitinase USP21) and by ALG3-mediated N-glycosylation at Asn176 that stabilizes it and promotes nuclear localization; in development, FOXD1 is essential for kidney stromal niche function, nephron progenitor differentiation, temporal retinal specification, optic chiasm formation, hypothalamic neuronal differentiation, and cell reprogramming to pluripotency, while in cancer it broadly promotes proliferation, EMT, stemness, angiogenesis, metabolic reprogramming (aerobic glycolysis), and therapy resistance across multiple tumor types."},"narrative":{"mechanistic_narrative":"FOXD1 is a forkhead/winged-helix transcription factor that governs cell-fate decisions during development and is broadly co-opted in cancer to drive proliferation, stemness, and therapy resistance [PMID:13678594, PMID:27569208]. It can act as a transcriptional activator or repressor depending on context, with its repressor function mapped to a dedicated repressor domain [PMID:19450575]. In renal and ocular development it is essential: it directly binds the PlGF promoter to support ureteric bud branching [PMID:13678594], represses decorin to permit BMP/SMAD-dependent nephron progenitor differentiation [PMID:24284212], marks the stromal lineage that gives rise to erythropoietin-producing interstitial cells [PMID:27088801], and is required in ventrotemporal retina to specify ipsilateral projections through Zic2/EphB1 and EphA6 [PMID:15509772, PMID:21490208]. Beyond the kidney and eye, FOXD1 patterns hypothalamic neuronal differentiation [PMID:29679559] and is a mid-stage mediator of reprogramming to pluripotency [PMID:24496101]. In tumors it directly transactivates targets that promote EMT and stemness (SNAI2), metabolic reprogramming toward aerobic glycolysis (SLC2A1/GLUT1, KIFC1), metastatic signaling (RalA), angiogenesis, and drug resistance (CTGF, BNIP3, ANXA3) [PMID:34348789, PMID:36057597, PMID:36229838, PMID:27569208, PMID:40083705]. FOXD1 expression and activity are set by multiple upstream inputs including YAP-TEAD, Sonic Hedgehog, Ets-1, and AKT signaling [PMID:30933975, PMID:29284139, PMID:9867825, PMID:11943768], while its protein abundance is controlled post-translationally by TRIM21-mediated K48-polyubiquitination opposed by the deubiquitinase USP21, and by ALG3-mediated N-glycosylation at Asn176 that stabilizes the protein and promotes its nuclear localization [PMID:38092733, PMID:35974001, PMID:40083705]. Patient-derived FOXD1 coding variants perturb its transactivation of implantation/placentation genes such as C3 and PlGF, linking FOXD1 dysfunction to recurrent pregnancy loss and related disorders [PMID:31395028, PMID:27805902].","teleology":[{"year":1996,"claim":"Established that FOXD1 expression is itself a regulated node, placing it downstream of the developmental/tumor-suppressor transcription factors WT-1 and p53.","evidence":"Promoter-luciferase deletion mapping in kidney-derived cell lines with WT-1, mutant and wild-type p53","pmids":["8702877"],"confidence":"Medium","gaps":["No direct protein-DNA binding confirmed for WT-1 element","Physiological relevance in vivo not tested"]},{"year":1999,"claim":"Identified Ets-1 as a direct upstream activator of the FOXD1 promoter, defining a second transcriptional input controlling FOXD1 levels.","evidence":"Reporter assays, in vitro DNase footprinting with recombinant Ets-1, and site-directed mutagenesis in HEK293","pmids":["9867825"],"confidence":"High","gaps":["Cellular context of Ets-1 regulation not defined","Does not address FOXD1 target genes"]},{"year":2002,"claim":"Showed FOXD1 integrates AKT/PKB and cAMP hormonal signals to activate the PKA RI-alpha 1b promoter, giving the first activity-mechanism placement of FOXD1 in a signaling circuit.","evidence":"Promoter deletion mapping, EMSA, and cotransfection with dominant-negative FOXD1 in adipocytes and Sertoli cells","pmids":["11943768"],"confidence":"High","gaps":["Direct phosphorylation of FOXD1 by AKT not shown","In vivo relevance untested"]},{"year":2003,"claim":"Defined the first physiologically validated direct target of FOXD1, linking renal stromal FOXD1 to ureteric bud branching via PlGF.","evidence":"Inducible expression plus microarray, promoter binding, BF-2 null mouse, and kidney organ culture","pmids":["13678594"],"confidence":"High","gaps":["Other stromal targets not enumerated","Mechanism of FOXD1 activation in stroma not addressed"]},{"year":2009,"claim":"Established FOXD1 as a domain-encoded transcriptional repressor controlling temporal retinal identity, clarifying its activator/repressor duality.","evidence":"In ovo electroporation with chimeric repressor/activator domain-swap mutants in chick retina","pmids":["19450575"],"confidence":"High","gaps":["Cofactors mediating repression unidentified","Does not address activator targets"]},{"year":2011,"claim":"Defined EphA6 as a downstream effector of FOXD1 directing retinal axon targeting, extending the retinal program from identity to projection mechanics.","evidence":"Conditional mouse genetics with axon tracing and marker immunostaining","pmids":["21490208"],"confidence":"High","gaps":["Direct vs indirect regulation of EphA6 not resolved"]},{"year":2014,"claim":"Showed FOXD1 is a required mid-stage mediator of somatic cell reprogramming, connecting it to the pluripotency network through Dax1.","evidence":"Knockout, shRNA, fate-mapping reporter, and reprogramming transcriptome analysis","pmids":["24496101"],"confidence":"High","gaps":["Direct targets driving Dax1 not mapped","Transient nature of FOXD1 expression mechanistically unexplained"]},{"year":2013,"claim":"Demonstrated by genetic epistasis that FOXD1 represses decorin to enable BMP/SMAD-dependent nephron progenitor differentiation, a defining renal developmental role.","evidence":"Foxd1/Dcn compound knockout rescue and BMP/SMAD pathway analysis in mouse","pmids":["24284212"],"confidence":"High","gaps":["Direct promoter binding of FOXD1 to Dcn not shown"]},{"year":2016,"claim":"Identified the FOXD1 stromal lineage as the source of erythropoietin-producing interstitial cells, integrating FOXD1 lineage with PHD/HIF-2 oxygen sensing.","evidence":"Foxd1-Cre lineage tracing with EPO reporter and PHD compound mutants/pharmacology","pmids":["27088801"],"confidence":"High","gaps":["FOXD1's direct transcriptional contribution to EPO regulation not defined"]},{"year":2016,"claim":"Extended FOXD1 from development into cancer, showing it sustains mesenchymal glioma stem cell identity via ALDH1A3, establishing the oncogenic stemness paradigm.","evidence":"shRNA, xenograft, transcriptional reporter, and cross-species RNAi epistasis","pmids":["27569208"],"confidence":"High","gaps":["Direct vs indirect ALDH1A3 regulation not fully resolved"]},{"year":2018,"claim":"Defined FOXD1 as a direct repressor of MICU1 controlling mitochondrial Ca2+ uptake and differentiation, linking FOXD1 to metabolic/Ca2+ control of stemness.","evidence":"Gain/loss-of-function in hESC/hiPSC and myocytes with Ca2+ imaging and bioenergetics","pmids":["30158529"],"confidence":"High","gaps":["Direct promoter binding evidence limited"]},{"year":2018,"claim":"Showed Sonic Hedgehog drives FOXD1 to repress Cdkn1c (p57), defining a Shh-FOXD1-Cdkn1c mitogenic circuit linking upstream morphogen signaling to proliferation.","evidence":"MEF knockout/overexpression, CDK pharmacology, and Cdkn1c Fox-enhancer reporter","pmids":["29284139"],"confidence":"High","gaps":["Mechanism of Shh-driven FOXD1 transcription not detailed"]},{"year":2019,"claim":"Placed FOXD1 downstream of YAP-TEAD in controlling cellular senescence, defining an anti-senescence/rejuvenation axis.","evidence":"CRISPR KO, ChIP for YAP/TEAD binding, senescence assays, and in vivo OA model","pmids":["30933975"],"confidence":"High","gaps":["FOXD1 senescence-suppressing targets in this context not fully mapped"]},{"year":2018,"claim":"Revealed a Gal-3/ERK1/2/FOXD1 feedback loop in which cytosolic ERK1/2 binds FOXD1 and shuttles it into the nucleus, providing the first cytoplasmic-to-nuclear control mechanism for FOXD1.","evidence":"Microarray, ChIP, ERK1/2-FOXD1 Co-IP, rescue, and xenograft in lung cancer","pmids":["31795213"],"confidence":"High","gaps":["Phosphorylation sites mediating ERK1/2 interaction not defined"]},{"year":2022,"claim":"Established post-translational control of FOXD1 abundance through the USP21 deubiquitinase opposing K48-polyubiquitination, explaining stabilization in mesenchymal GBM.","evidence":"Co-IP, K48 ubiquitination assay, USP21 knockdown with FOXD1 rescue, and disulfiram in vivo","pmids":["35974001"],"confidence":"High","gaps":["The E3 ligase opposed by USP21 not identified in this study"]},{"year":2022,"claim":"Defined FOXD1-RalA as a direct metastatic axis, with RalA assembling an ANXA2-Src complex driving ERK signaling and circulating tumor cell formation.","evidence":"ChIP-seq, CUT&Tag, GST-pulldown, Co-IP, and in vivo CTC/metastasis models in breast cancer","pmids":["36229838"],"confidence":"High","gaps":["Generality of the RalA axis across tumor types untested"]},{"year":2021,"claim":"Connected FOXD1 to cell-cycle execution at G2/M and genome stability via control of histone H3 phosphorylation in ccRCC.","evidence":"CRISPR knockout in 786-O with cell-cycle, phospho-H3, DNA-damage, metabolic, and xenograft readouts","pmids":["33761914"],"confidence":"High","gaps":["Direct mechanism linking FOXD1 to histone H3 phosphorylation unresolved"]},{"year":2025,"claim":"Identified ALG3-mediated N-glycosylation at Asn176 as a stabilizing modification that promotes FOXD1 nuclear localization and BNIP3-driven mitophagy/drug resistance, adding glycosylation to the FOXD1 regulatory repertoire.","evidence":"Co-IP, glycosylation site mapping, nuclear fractionation, ChIP/luciferase for BNIP3, and xenograft in NPC","pmids":["40083705"],"confidence":"High","gaps":["Whether glycosylation alters DNA-binding affinity not addressed"]},{"year":2019,"claim":"Linked FOXD1 coding variants to human reproductive pathology by showing they impair transactivation of implantation/placentation genes.","evidence":"Patient sequencing plus reporter transactivation assays with mutant FOXD1 on C3 and PlGF promoters","pmids":["31395028","27805902"],"confidence":"Medium","gaps":["Causality vs association at population scale not established","In vivo placental phenotype of variants untested"]},{"year":null,"claim":"It remains unresolved how FOXD1 selects between activator and repressor modes at individual loci and which cofactors and chromatin contexts dictate its divergent developmental versus oncogenic target programs.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unifying structural/cofactor model for FOXD1 activator vs repressor switching","Genome-wide direct target maps across tissues sparse","Integration of the multiple PTM inputs (ubiquitination, glycosylation, ERK shuttling) into one regulatory logic undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,6,8,14,15,18,19,24,27,30,35,40]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,18,27,30,37,43,44]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[18,33,40]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[18,33]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,8,14,15,27,30]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,7,8,12,16,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[11,24,30,32,41]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[29,35,40]}],"complexes":[],"partners":["USP21","TRIM21","ALG3","ERK1/2","BETA-CATENIN","YAP","TEAD"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q16676","full_name":"Forkhead box protein D1","aliases":["Forkhead-related protein FKHL8","Forkhead-related transcription factor 4","FREAC-4"],"length_aa":465,"mass_kda":46.1,"function":"Transcription factor involved in regulation of gene expression in a variety of processes, including formation of positional identity in the developing retina, regionalization of the optic chiasm, morphogenesis of the kidney, and neuralization of ectodermal cells (By similarity). Involved in transcriptional activation of PGF and C3 genes (PubMed:27805902)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q16676/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FOXD1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":77,"dependency_fraction":0.012987012987012988},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FOXD1","total_profiled":1310},"omim":[{"mim_id":"601091","title":"FORKHEAD BOX D1; FOXD1","url":"https://www.omim.org/entry/601091"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FOXD1"},"hgnc":{"alias_symbol":["FREAC4"],"prev_symbol":["FKHL8"]},"alphafold":{"accession":"Q16676","domains":[{"cath_id":"1.10.10.10","chopping":"131-189_196-206","consensus_level":"high","plddt":92.7067,"start":131,"end":206}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16676","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q16676-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q16676-F1-predicted_aligned_error_v6.png","plddt_mean":56.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FOXD1","jax_strain_url":"https://www.jax.org/strain/search?query=FOXD1"},"sequence":{"accession":"Q16676","fasta_url":"https://rest.uniprot.org/uniprotkb/Q16676.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q16676/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q16676"}},"corpus_meta":[{"pmid":"30933975","id":"PMC_30933975","title":"Up-regulation of FOXD1 by YAP alleviates senescence and osteoarthritis.","date":"2019","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/30933975","citation_count":137,"is_preprint":false},{"pmid":"30792394","id":"PMC_30792394","title":"CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30792394","citation_count":137,"is_preprint":false},{"pmid":"27569208","id":"PMC_27569208","title":"FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27569208","citation_count":128,"is_preprint":false},{"pmid":"24284212","id":"PMC_24284212","title":"FOXD1 promotes nephron progenitor differentiation by repressing decorin in the embryonic kidney.","date":"2013","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24284212","citation_count":118,"is_preprint":false},{"pmid":"15509772","id":"PMC_15509772","title":"Foxd1 is required for proper formation of the optic chiasm.","date":"2004","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15509772","citation_count":92,"is_preprint":false},{"pmid":"27088801","id":"PMC_27088801","title":"Distinct subpopulations of FOXD1 stroma-derived cells regulate renal erythropoietin.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27088801","citation_count":92,"is_preprint":false},{"pmid":"36057597","id":"PMC_36057597","title":"FOXD1 facilitates pancreatic cancer cell proliferation, invasion, and metastasis by regulating GLUT1-mediated aerobic glycolysis.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36057597","citation_count":80,"is_preprint":false},{"pmid":"30635407","id":"PMC_30635407","title":"MicroRNA-92a-1-5p increases CDX2 by targeting FOXD1 in bile acids-induced gastric intestinal metaplasia.","date":"2019","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/30635407","citation_count":75,"is_preprint":false},{"pmid":"25462566","id":"PMC_25462566","title":"FOXD1 promotes breast cancer proliferation and chemotherapeutic drug resistance by targeting p27.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25462566","citation_count":65,"is_preprint":false},{"pmid":"8825632","id":"PMC_8825632","title":"Chromosomal localization of six human forkhead genes, freac-1 (FKHL5), -3 (FKHL7), -4 (FKHL8), -5 (FKHL9), -6 (FKHL10), and -8 (FKHL12).","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8825632","citation_count":65,"is_preprint":false},{"pmid":"24226518","id":"PMC_24226518","title":"RBP-J in FOXD1+ renal stromal progenitors is crucial for the proper development and assembly of the kidney vasculature and glomerular mesangial cells.","date":"2013","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24226518","citation_count":62,"is_preprint":false},{"pmid":"32460412","id":"PMC_32460412","title":"FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway.","date":"2020","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32460412","citation_count":61,"is_preprint":false},{"pmid":"24496101","id":"PMC_24496101","title":"Foxd1 is a mediator and indicator of the cell reprogramming process.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/24496101","citation_count":61,"is_preprint":false},{"pmid":"26312147","id":"PMC_26312147","title":"The FOXD1 lineage of kidney perivascular cells and myofibroblasts: functions and responses to injury.","date":"2014","source":"Kidney international supplements","url":"https://pubmed.ncbi.nlm.nih.gov/26312147","citation_count":59,"is_preprint":false},{"pmid":"21490208","id":"PMC_21490208","title":"Transcription factor Foxd1 is required for the specification of the temporal retina in mammals.","date":"2011","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21490208","citation_count":54,"is_preprint":false},{"pmid":"31252264","id":"PMC_31252264","title":"SP1-mediated long noncoding RNA POU3F3 accelerates the cervical cancer through miR-127-5p/FOXD1.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31252264","citation_count":45,"is_preprint":false},{"pmid":"29959475","id":"PMC_29959475","title":"The multisystemic functions of FOXD1 in development and disease.","date":"2018","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/29959475","citation_count":44,"is_preprint":false},{"pmid":"13678594","id":"PMC_13678594","title":"Transcriptional activation of placental growth factor by the forkhead/winged helix transcription factor FoxD1.","date":"2003","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/13678594","citation_count":44,"is_preprint":false},{"pmid":"29620165","id":"PMC_29620165","title":"FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29620165","citation_count":42,"is_preprint":false},{"pmid":"32669972","id":"PMC_32669972","title":"LncRNA OIP5-AS1 promotes the malignancy of pancreatic ductal adenocarcinoma via regulating miR-429/FOXD1/ERK pathway.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/32669972","citation_count":39,"is_preprint":false},{"pmid":"35263586","id":"PMC_35263586","title":"Deletion of STAT3 from Foxd1 cell population protects mice from kidney fibrosis by inhibiting pericytes trans-differentiation and migration.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35263586","citation_count":37,"is_preprint":false},{"pmid":"32954854","id":"PMC_32954854","title":"METTL3 contributes to renal ischemia-reperfusion injury by regulating Foxd1 methylation.","date":"2020","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32954854","citation_count":36,"is_preprint":false},{"pmid":"28651950","id":"PMC_28651950","title":"The loss of Krüppel-like factor 15 in Foxd1+ stromal cells exacerbates kidney fibrosis.","date":"2017","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/28651950","citation_count":36,"is_preprint":false},{"pmid":"30158529","id":"PMC_30158529","title":"FOXD1-dependent MICU1 expression regulates mitochondrial activity and cell differentiation.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30158529","citation_count":35,"is_preprint":false},{"pmid":"33309645","id":"PMC_33309645","title":"LncRNA NORAD promotes proliferation, migration and angiogenesis of hepatocellular carcinoma cells through targeting miR-211-5p/FOXD1/VEGF-A axis.","date":"2020","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/33309645","citation_count":35,"is_preprint":false},{"pmid":"11943768","id":"PMC_11943768","title":"Mechanisms of FOXC2- and FOXD1-mediated regulation of the RI alpha subunit of cAMP-dependent protein kinase include release of transcriptional repression and activation by protein kinase B alpha and cAMP.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11943768","citation_count":35,"is_preprint":false},{"pmid":"31102349","id":"PMC_31102349","title":"LncRNA FOXD1-AS1 acts as a potential oncogenic biomarker in glioma.","date":"2019","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/31102349","citation_count":34,"is_preprint":false},{"pmid":"29945868","id":"PMC_29945868","title":"Hedgehog-GLI signaling in Foxd1-positive stromal cells promotes murine nephrogenesis via TGFβ signaling.","date":"2018","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/29945868","citation_count":34,"is_preprint":false},{"pmid":"30562753","id":"PMC_30562753","title":"FOXD1 Promotes Cell Growth and Metastasis by Activation of Vimentin in NSCLC.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30562753","citation_count":33,"is_preprint":false},{"pmid":"29936179","id":"PMC_29936179","title":"MiR-30a-5p inhibits osteosarcoma cell proliferation and migration by targeting FOXD1.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29936179","citation_count":32,"is_preprint":false},{"pmid":"30225541","id":"PMC_30225541","title":"MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1.","date":"2018","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30225541","citation_count":30,"is_preprint":false},{"pmid":"35974001","id":"PMC_35974001","title":"USP21 promotes self-renewal and tumorigenicity of mesenchymal glioblastoma stem cells by deubiquitinating and stabilizing FOXD1.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35974001","citation_count":29,"is_preprint":false},{"pmid":"31795213","id":"PMC_31795213","title":"FOXD1 and Gal-3 Form a Positive Regulatory Loop to Regulate Lung Cancer Aggressiveness.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31795213","citation_count":29,"is_preprint":false},{"pmid":"29679559","id":"PMC_29679559","title":"Foxd1 is required for terminal differentiation of anterior hypothalamic neuronal subtypes.","date":"2018","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/29679559","citation_count":29,"is_preprint":false},{"pmid":"16585573","id":"PMC_16585573","title":"Coordination of NF-kappaB and NFAT antagonism by the forkhead transcription factor Foxd1.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16585573","citation_count":28,"is_preprint":false},{"pmid":"30110134","id":"PMC_30110134","title":"Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation.","date":"2018","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30110134","citation_count":27,"is_preprint":false},{"pmid":"9867825","id":"PMC_9867825","title":"The kidney-expressed winged helix transcription factor FREAC-4 is regulated by Ets-1. A possible role in kidney development.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9867825","citation_count":27,"is_preprint":false},{"pmid":"19450575","id":"PMC_19450575","title":"Functional mode of FoxD1/CBF2 for the establishment of temporal retinal specificity in the developing chick retina.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19450575","citation_count":26,"is_preprint":false},{"pmid":"32294305","id":"PMC_32294305","title":"miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.","date":"2020","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/32294305","citation_count":25,"is_preprint":false},{"pmid":"36229838","id":"PMC_36229838","title":"FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/36229838","citation_count":25,"is_preprint":false},{"pmid":"8702877","id":"PMC_8702877","title":"Characterization of the human forkhead gene FREAC-4. Evidence for regulation by Wilms' tumor suppressor gene (WT-1) and p53.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702877","citation_count":24,"is_preprint":false},{"pmid":"32967107","id":"PMC_32967107","title":"FOXD1 Repression Potentiates Radiation Effectiveness by Downregulating G3BP2 Expression and Promoting the Activation of TXNIP-Related Pathways in Oral Cancer.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32967107","citation_count":23,"is_preprint":false},{"pmid":"28847650","id":"PMC_28847650","title":"Hypoxia-inducible factor prolyl-4-hydroxylation in FOXD1 lineage cells is essential for normal kidney development.","date":"2017","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/28847650","citation_count":23,"is_preprint":false},{"pmid":"34348789","id":"PMC_34348789","title":"FOXD1 promotes EMT and cell stemness of oral squamous cell carcinoma by transcriptional activation of SNAI2.","date":"2021","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/34348789","citation_count":22,"is_preprint":false},{"pmid":"32351986","id":"PMC_32351986","title":"miR-30a-5p Inhibits Proliferation and Migration of Lung Squamous Cell Carcinoma Cells by Targeting FOXD1.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/32351986","citation_count":22,"is_preprint":false},{"pmid":"33837564","id":"PMC_33837564","title":"FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor.","date":"2021","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33837564","citation_count":19,"is_preprint":false},{"pmid":"23284914","id":"PMC_23284914","title":"The forkhead transcription factor, Foxd1, is necessary for pituitary luteinizing hormone expression in mice.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23284914","citation_count":19,"is_preprint":false},{"pmid":"36652050","id":"PMC_36652050","title":"BMSC-Derived Exosomes Carrying lncRNA-ZFAS1 Alleviate Pulmonary Ischemia/Reperfusion Injury by UPF1-Mediated mRNA Decay of FOXD1.","date":"2023","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/36652050","citation_count":18,"is_preprint":false},{"pmid":"31395028","id":"PMC_31395028","title":"FOXD1 mutations are related to repeated implantation failure, intra-uterine growth restriction and preeclampsia.","date":"2019","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/31395028","citation_count":17,"is_preprint":false},{"pmid":"27805902","id":"PMC_27805902","title":"Association of FOXD1 variants with adverse pregnancy outcomes in mice and humans.","date":"2016","source":"Open biology","url":"https://pubmed.ncbi.nlm.nih.gov/27805902","citation_count":17,"is_preprint":false},{"pmid":"33761914","id":"PMC_33761914","title":"FOXD1 regulates cell division in clear cell renal cell carcinoma.","date":"2021","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33761914","citation_count":16,"is_preprint":false},{"pmid":"33078907","id":"PMC_33078907","title":"LINC01133 promotes the progression of cervical cancer via regulating miR-30a-5p/FOXD1.","date":"2020","source":"Asia-Pacific journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33078907","citation_count":16,"is_preprint":false},{"pmid":"28665931","id":"PMC_28665931","title":"Foxd1 is an upstream regulator of the renin-angiotensin system during metanephric kidney development.","date":"2017","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/28665931","citation_count":15,"is_preprint":false},{"pmid":"34403535","id":"PMC_34403535","title":"FOXD1-AS1 upregulates FOXD1 to promote oral squamous cell carcinoma progression.","date":"2021","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/34403535","citation_count":14,"is_preprint":false},{"pmid":"38167126","id":"PMC_38167126","title":"LncRNA FOXD1-AS1 regulates pancreatic cancer stem cell properties and 5-FU resistance by regulating the miR-570-3p/SPP1 axis as a ceRNA.","date":"2024","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/38167126","citation_count":14,"is_preprint":false},{"pmid":"34269372","id":"PMC_34269372","title":"FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.","date":"2021","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/34269372","citation_count":13,"is_preprint":false},{"pmid":"30545632","id":"PMC_30545632","title":"Autophagy in FOXD1 stroma-derived cells regulates renal fibrosis through TGF-β and NLRP3 inflammasome pathway.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30545632","citation_count":13,"is_preprint":false},{"pmid":"32568181","id":"PMC_32568181","title":"FOXD1, negatively regulated by miR-186, promotes the proliferation, metastasis and radioresistance of nasopharyngeal carcinoma cells.","date":"2020","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/32568181","citation_count":13,"is_preprint":false},{"pmid":"37203394","id":"PMC_37203394","title":"FOXD1 promotes chemotherapy resistance by enhancing cell stemness in colorectal cancer through β‑catenin nuclear localization.","date":"2023","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/37203394","citation_count":12,"is_preprint":false},{"pmid":"30810761","id":"PMC_30810761","title":"Metanephric mesenchyme-derived Foxd1+ mesangial precursor cells alleviate mesangial proliferative glomerulonephritis.","date":"2019","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/30810761","citation_count":12,"is_preprint":false},{"pmid":"37906341","id":"PMC_37906341","title":"SUMOylation of RALY promotes vasculogenic mimicry in glioma cells via the FOXD1/DKK1 pathway.","date":"2023","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/37906341","citation_count":11,"is_preprint":false},{"pmid":"29284139","id":"PMC_29284139","title":"Coordinated d-cyclin/Foxd1 activation drives mitogenic activity of the Sonic Hedgehog signaling pathway.","date":"2017","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/29284139","citation_count":11,"is_preprint":false},{"pmid":"30641031","id":"PMC_30641031","title":"The Sertoli cell marker FOXD1 regulates testis development and function in the chicken.","date":"2019","source":"Reproduction, fertility, and development","url":"https://pubmed.ncbi.nlm.nih.gov/30641031","citation_count":10,"is_preprint":false},{"pmid":"37563111","id":"PMC_37563111","title":"miR-30e-5p-mediated FOXD1 promotes cell proliferation by blocking cellular senescence and apoptosis through p21/CDK2/Rb signaling in head and neck carcinoma.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37563111","citation_count":10,"is_preprint":false},{"pmid":"36520654","id":"PMC_36520654","title":"Foxd1-dependent induction of a temporal retinal character is required for visual function.","date":"2022","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36520654","citation_count":10,"is_preprint":false},{"pmid":"33294261","id":"PMC_33294261","title":"Long non-coding RNA FOXD1-AS1 promotes the progression and glycolysis of nasopharyngeal carcinoma by sustaining FOXD1 expression.","date":"2020","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33294261","citation_count":10,"is_preprint":false},{"pmid":"34258523","id":"PMC_34258523","title":"Lineage tracing of Foxd1-expressing embryonic progenitors to assess the role of divergent embryonic lineages on adult dermal fibroblast function.","date":"2021","source":"FASEB bioAdvances","url":"https://pubmed.ncbi.nlm.nih.gov/34258523","citation_count":10,"is_preprint":false},{"pmid":"34674391","id":"PMC_34674391","title":"FOXD1-AS1 promotes malignant behaviours of prostate cancer cells via the miR-3167/YWHAZ axis.","date":"2021","source":"Andrologia","url":"https://pubmed.ncbi.nlm.nih.gov/34674391","citation_count":9,"is_preprint":false},{"pmid":"37234983","id":"PMC_37234983","title":"FOXD1 is associated with poor outcome and maintains tumor-promoting enhancer-gene programs in basal-like breast cancer.","date":"2023","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37234983","citation_count":9,"is_preprint":false},{"pmid":"29667914","id":"PMC_29667914","title":"Inactivation of MAP3K7 in FOXD1-expressing cells results in loss of mesangial PDGFRΒ and juvenile kidney scarring.","date":"2018","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29667914","citation_count":9,"is_preprint":false},{"pmid":"37840569","id":"PMC_37840569","title":"LMNB1 targets FOXD1 to promote progression of prostate cancer.","date":"2023","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37840569","citation_count":8,"is_preprint":false},{"pmid":"34446141","id":"PMC_34446141","title":"Long Non-Coding RNA OIP5-AS1 Inhibits the Proliferation and Migration of Esophageal Squamous Carcinoma Cells by Targeting FOXD1/miR-30a-5p Axis and the Effect of Micro- and Nano-Particles on Targeting Transfection System.","date":"2021","source":"Journal of biomedical nanotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/34446141","citation_count":8,"is_preprint":false},{"pmid":"40401803","id":"PMC_40401803","title":"Tumor-associated macrophage-derived exosomes modulate the immunotherapeutic sensitivity of SHH-medulloblastoma by targeting m6A-modified FOXD1.","date":"2025","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40401803","citation_count":7,"is_preprint":false},{"pmid":"37772431","id":"PMC_37772431","title":"Hedgehog signalling in Foxd1+ embryonic kidney stromal progenitors controls nephron formation via Cxcl12 and Wnt5a.","date":"2023","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37772431","citation_count":7,"is_preprint":false},{"pmid":"36172670","id":"PMC_36172670","title":"FOXD1-mTOR Signaling Pathway on Oral Squamous Cell Carcinoma and Its Inhibition by Rosemary Extract (Invitro-Study).","date":"2022","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/36172670","citation_count":6,"is_preprint":false},{"pmid":"28621426","id":"PMC_28621426","title":"FoxD1 protein interacts with Wnt and BMP signaling to differentially pattern mesoderm and neural tissue.","date":"2017","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/28621426","citation_count":6,"is_preprint":false},{"pmid":"35126932","id":"PMC_35126932","title":"FOXD1 Regulates the Sensitivity of Cetuximab by Regulating the Expression of EGFR in Head and Neck Squamous Cell Cancer.","date":"2022","source":"Journal of healthcare engineering","url":"https://pubmed.ncbi.nlm.nih.gov/35126932","citation_count":6,"is_preprint":false},{"pmid":"35738443","id":"PMC_35738443","title":"Silencing effects of FOXD1 inhibit metastatic potentials of the PCa via N-cadherin - Wnt/β-catenin crosstalk.","date":"2022","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/35738443","citation_count":6,"is_preprint":false},{"pmid":"35954332","id":"PMC_35954332","title":"FOXD1 Is a Transcription Factor Important for Uveal Melanocyte Development and Associated with High-Risk Uveal Melanoma.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35954332","citation_count":6,"is_preprint":false},{"pmid":"22140378","id":"PMC_22140378","title":"FOXD1 Duplication Causes Branchial Defects and Interacts with the TFAP2A Gene Implicated in the Branchio-Oculo-Facial Syndrome in Causing Eye Effects in Zebrafish.","date":"2011","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/22140378","citation_count":6,"is_preprint":false},{"pmid":"39226736","id":"PMC_39226736","title":"FoxD1 expression identifies a distinct subset of hepatic stellate cells involved in liver fibrosis.","date":"2024","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39226736","citation_count":5,"is_preprint":false},{"pmid":"36010951","id":"PMC_36010951","title":"Targets for Renal Carcinoma Growth Control Identified by Screening FOXD1 Cell Proliferation Pathways.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36010951","citation_count":5,"is_preprint":false},{"pmid":"30969804","id":"PMC_30969804","title":"Apparently normal kidney development in mice with conditional disruption of ANG II-AT1 receptor genes in FoxD1-positive stroma cell precursors.","date":"2019","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30969804","citation_count":5,"is_preprint":false},{"pmid":"38692456","id":"PMC_38692456","title":"Waterpipe smoke condensate induces epithelial-mesenchymal transformation and promotes metastasis of oral cancer by FOXD1 expression.","date":"2024","source":"Journal of stomatology, oral and maxillofacial surgery","url":"https://pubmed.ncbi.nlm.nih.gov/38692456","citation_count":4,"is_preprint":false},{"pmid":"40210238","id":"PMC_40210238","title":"Neural crest-associated gene FOXD1 induces an immunosuppressive microenvironment by regulating myeloid-derived suppressor cells in melanoma.","date":"2025","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40210238","citation_count":4,"is_preprint":false},{"pmid":"34767742","id":"PMC_34767742","title":"LINC00641 contributes to nasopharyngeal carcinoma cell malignancy through FOXD1 upregulation at the post-transcriptional level.","date":"2021","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/34767742","citation_count":4,"is_preprint":false},{"pmid":"40241815","id":"PMC_40241815","title":"Acupotomy Ameliorates KOA Related Chondrocyte Premature Senescence Through YAP/FOXD1 Pathway.","date":"2025","source":"Journal of pain research","url":"https://pubmed.ncbi.nlm.nih.gov/40241815","citation_count":4,"is_preprint":false},{"pmid":"38092733","id":"PMC_38092733","title":"The TRIM21-FOXD1-BCL-2 axis underlies hyperglycaemic cell death and diabetic tissue damage.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38092733","citation_count":3,"is_preprint":false},{"pmid":"36335435","id":"PMC_36335435","title":"FOXD1 is required for 3D patterning of the kidney interstitial matrix.","date":"2023","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/36335435","citation_count":3,"is_preprint":false},{"pmid":"39541848","id":"PMC_39541848","title":"FOXD1 activates KIFC1 to modulate aerobic glycolysis and reinforce cisplatin resistance of breast cancer.","date":"2024","source":"Reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/39541848","citation_count":3,"is_preprint":false},{"pmid":"32291573","id":"PMC_32291573","title":"Correction to: FoxD1-driven CCN2 deletion causes axial skeletal deformities, pulmonary hypoplasia, and neonatal asphyctic death.","date":"2020","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/32291573","citation_count":3,"is_preprint":false},{"pmid":"40083705","id":"PMC_40083705","title":"Targeting ALG3/FOXD1/BNIP3 Axis Prevents Mitophagy and Gemcitabine Resistance of Nasopharyngeal Carcinoma.","date":"2025","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40083705","citation_count":2,"is_preprint":false},{"pmid":"40999468","id":"PMC_40999468","title":"The FOXD1/NAT10 positive feedback loop drives nasopharyngeal carcinoma progression.","date":"2025","source":"Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/40999468","citation_count":2,"is_preprint":false},{"pmid":"39805916","id":"PMC_39805916","title":"Transcription factor FOXD1 and miRNA-204-5p play a major role in B4GALNT2 downregulation in colon cancer.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39805916","citation_count":2,"is_preprint":false},{"pmid":"40095055","id":"PMC_40095055","title":"FOXD1-activated ANXA3 facilitates cisplatin resistance of lung cancer cells via promoting ANXA4 expression.","date":"2025","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40095055","citation_count":2,"is_preprint":false},{"pmid":"32020419","id":"PMC_32020419","title":"FoxD1-driven CCN2 deletion causes axial skeletal deformities, pulmonary hypoplasia, and neonatal asphyctic death.","date":"2020","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/32020419","citation_count":2,"is_preprint":false},{"pmid":"35247391","id":"PMC_35247391","title":"Deletion of hypoxia-inducible factor prolyl 4-hydroxylase 2 in FoxD1-lineage mesenchymal cells leads to congenital truncal alopecia.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35247391","citation_count":2,"is_preprint":false},{"pmid":"41358813","id":"PMC_41358813","title":"Defects in nephrogenesis result in an expansion of the Foxd1+ stromal progenitor population.","date":"2026","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/41358813","citation_count":1,"is_preprint":false},{"pmid":"39269873","id":"PMC_39269873","title":"Echinacoside inhibits hepatocellular carcinoma progression by targeting the miR-30c-5p/FOXD1/KLF12 axis.","date":"2025","source":"Technology and health care : official journal of the European Society for Engineering and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39269873","citation_count":1,"is_preprint":false},{"pmid":"39211232","id":"PMC_39211232","title":"The transcription factor TCF21 is necessary for adoption of cell fates by Foxd1+ stromal progenitors during kidney development.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39211232","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52701,"output_tokens":11463,"usd":0.165024,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":22369,"output_tokens":5233,"usd":0.121335,"stage2_stop_reason":"end_turn"},"total_usd":0.286359,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"FoxD1 (BF-2) directly binds to a conserved HNF3β site in the Placental Growth Factor (PlGF) promoter and activates its transcription; PlGF is absent in BF-2 null kidney stroma, and exogenous PlGF stimulates ureteric bud branching in vitro, establishing PlGF as a direct, physiologically relevant transcriptional target of FoxD1 in renal stromal cells.\",\n      \"method\": \"Inducible FoxD1 expression + microarray, promoter binding assay, BF-2 null mouse, in vitro kidney organ culture\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (microarray, promoter binding, null mouse, organ culture) in one rigorous study establishing direct transcriptional regulation and physiological relevance\",\n      \"pmids\": [\"13678594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The FOXD1 (FREAC-4) promoter is regulated by the transcription factor Ets-1; three Ets-1 cis-elements within the first 152 nucleotides upstream of the transcription start site mediate ~6-fold induction, and overexpression of Ets-1 in HEK293 cells is sufficient to increase FREAC-4 mRNA levels.\",\n      \"method\": \"Transfection reporter assay, DNase I in vitro protection (footprinting) with recombinant Ets-1, site-directed mutagenesis of Ets-1 binding sites, mRNA quantification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro footprinting with recombinant protein plus mutagenesis and cell transfection, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"9867825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The FOXD1 (FREAC-4) promoter contains regulatory elements responsive to WT-1 (3-fold induction) and mutant p53 (7-fold induction), while wild-type p53 represses it ~4-fold; a deletion series identified a fragment necessary for WT-1 inducibility that contains at least one WT-1 cis-element.\",\n      \"method\": \"Promoter-luciferase reporter cotransfection in kidney-derived cell lines (293, COS-7), promoter deletion series, RNase protection assay for transcription start site\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean reporter + deletion mapping in relevant cell lines, single lab, no in vitro protein binding confirmed\",\n      \"pmids\": [\"8702877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"FOXD1 activates the RI-alpha subunit of cAMP-dependent PKA via the 1b promoter in Sertoli cells through sequences downstream of the transcription start site; protein kinase B alpha/Akt1 strongly potentiates this effect, and an inactive FOXD1 mutant reduces cAMP-mediated induction of the RI-alpha 1b reporter, placing FOXD1 as an integrator of PKB and cAMP hormonal signals.\",\n      \"method\": \"Promoter deletion mapping, bandshift assay (EMSA), cotransfection reporter assays in 3T3-L1 adipocytes and Sertoli cells, dominant-negative FOXD1 mutant\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — deletion mapping, EMSA, cotransfection with mutant construct, two cell types, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"11943768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Foxd1 is required in ventrotemporal (VT) retina for specification of the ipsilateral retinal projection: Foxd1-null mice lose Zic2 and EphB1 expression in VT retina, the Foxg1 domain expands, and VT RGC axons fail to be repulsed by chiasm cells in co-culture, aberrantly projecting contralaterally. Foxd1 also patterns the ventral diencephalon where the optic chiasm forms.\",\n      \"method\": \"Foxd1 knockout mouse, immunostaining, retina-chiasm co-culture repulsion assay, in vivo axon tracing\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function mouse with multiple molecular readouts and functional co-culture assay, replicated across several experimental approaches\",\n      \"pmids\": [\"15509772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Foxd1 coordinates suppression of both NF-AT and NF-κB pathways in T cells: Foxd1 deficiency results in increased NF-AT activity correlated with reduced casein kinase 1 (an NF-AT inhibitory kinase), and increased NF-κB activity correlated with reduced Foxj1 (which regulates IκBβ). Foxd1-null mice develop multiorgan systemic inflammation and exaggerated Th-cell cytokine production.\",\n      \"method\": \"Foxd1 knockout mouse, T cell functional assays (cytokine production, MLR proliferation), NF-AT and NF-κB activity assays, epistasis analysis with casein kinase 1 and Foxj1\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with defined cellular phenotype and pathway placement, single lab, multiple pathway readouts\",\n      \"pmids\": [\"16585573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In the developing chick retina, FoxD1 (CBF2) acts as a transcriptional repressor to establish temporal retinal identity: misexpression of FoxD1 represses FoxG1, GH6, SOHo1, and ephrin-A5, and induces EphA3. Chimeric mutant studies showed FoxD1 functions through its repressor domain. FGF and Wnt signaling induce region-specific FoxD1 expression in the optic vesicle.\",\n      \"method\": \"In ovo electroporation (gain-of-function), chimeric FoxD1 repressor/activator domain mutants, immunostaining in chick\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — chimeric domain-swap mutagenesis combined with in vivo misexpression, identifies mechanism (transcriptional repression) and downstream targets\",\n      \"pmids\": [\"19450575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In mouse, Foxd1 is necessary for temporal retinal identity and ipsilateral axonal projection; EphA6 is identified as a downstream effector of Foxd1 that directs temporal axons to the rostral colliculus.\",\n      \"method\": \"Foxd1 conditional mouse genetics, axon tracing, immunostaining for EphA6 and retinal identity markers\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function mouse with defined molecular target (EphA6) and functional axon-projection phenotype\",\n      \"pmids\": [\"21490208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FOXD1 represses the gene encoding decorin (DCN) in cortical interstitial cells of the embryonic kidney; in Foxd1-null mice DCN is de-repressed and antagonizes BMP/SMAD signaling required for nephron progenitor cell differentiation. Compound genetic inactivation of Dcn partially rescues the nephron progenitor differentiation defect in Foxd1 null kidneys.\",\n      \"method\": \"Foxd1 knockout mouse, target gene screening, compound Foxd1/Dcn double knockout, BMP/SMAD signaling analysis\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double knockout rescue plus molecular pathway analysis, multiple methods in one rigorous study\",\n      \"pmids\": [\"24284212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Foxd1 is required as a mediator of cell reprogramming to iPSCs: knockout of Foxd1 inhibits downstream transcriptional events including Dax1 expression (a component of the pluripotency autoregulatory network), and fate-mapping shows >95% of iPSC colonies derive from transiently Foxd1-positive cells at a mid-stage of reprogramming.\",\n      \"method\": \"Foxd1 knockout, shRNA knockdown, fate-mapping with Foxd1-reporter, transcriptome analysis during reprogramming\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO with defined transcriptional phenotype (Dax1) plus fate-mapping, multiple orthogonal methods\",\n      \"pmids\": [\"24496101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FOXD1 promotes breast cancer cell proliferation and chemoresistance by inducing G1-to-S phase transition through targeting p27 expression (decreasing p27 levels).\",\n      \"method\": \"shRNA knockdown and overexpression in breast cancer cell lines, cell cycle analysis, p27 western blot\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — KD/OE with defined phenotype and molecular target, single lab, no ChIP or direct promoter assay reported in abstract\",\n      \"pmids\": [\"25462566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXD1 is expressed predominantly in mesenchymal (MES) glioma stem cells and regulates the transcriptional activity of ALDH1A3, an established marker of MES GSCs; shRNA attenuation of FOXD1 abolishes MES GSC clonogenicity in vitro and in vivo.\",\n      \"method\": \"shRNA, in vitro sphere/clonogenicity assay, in vivo xenograft, transcriptional reporter for ALDH1A3, Drosophila RNAi epistasis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (shRNA, in vivo xenograft, transcriptional assay, cross-species RNAi epistasis) in one study\",\n      \"pmids\": [\"27569208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Renal interstitial cells with EPO-producing capacity are entirely derived from FOXD1-expressing stroma; PHD2 inactivation alone in FOXD1-lineage cells induces renal Epo in a limited number of interstitial cells, and additional heterozygous deficiency for PHD1 and PHD3 increases the EPO-producing cell fraction, placing PHD/HIF-2 regulation of EPO production within the FOXD1 stromal lineage.\",\n      \"method\": \"Conditional Cre/lox knockout (Foxd1-Cre), EPO reporter fate mapping, pharmacological PHD inhibition, genetic PHD compound mutants\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — lineage-specific conditional genetics with multiple PHD allele combinations and pharmacological validation\",\n      \"pmids\": [\"27088801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Foxd1 is an upstream positive regulator of the renin-angiotensin system (RAS) during metanephric kidney development: Foxd1-null embryonic kidneys show decreased renin, AGT, ACE, and AT1R expression, and overexpression of Foxd1 in mesenchymal MK4 cells increases these RAS components in vitro.\",\n      \"method\": \"Foxd1 knockout mouse, qRT-PCR, western blot, immunohistochemistry, Foxd1 overexpression in MK4 cells, ex vivo ureteric bud branching assay\",\n      \"journal\": \"Pediatric research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse combined with gain-of-function cell experiment, multiple RAS targets assessed, single lab\",\n      \"pmids\": [\"28665931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FOXD1 is transcriptionally regulated by canonical Sonic Hedgehog (Shh) signaling; Foxd1 is required downstream of Shh for the proliferative response — Foxd1 deletion abrogates SHH-induced proliferation, whereas FOXD1 overexpression alone is sufficient to induce proliferation. FOXD1 reduces reporter activity of a Fox enhancer in the second intron of Cdkn1c (p57), and Shh pathway activation of Foxd1 is followed by Cdkn1c downregulation, defining a Shh-Foxd1-Cdkn1c mitogenic circuit.\",\n      \"method\": \"Mouse embryonic fibroblasts, Foxd1 knockout, FOXD1 overexpression, CDK inhibitor pharmacology, luciferase reporter for Cdkn1c Fox enhancer, cranial neural crest cell experiments\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — KO plus OE with pharmacological rescue, direct promoter reporter assay, multiple cell contexts, single lab\",\n      \"pmids\": [\"29284139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FOXD1 directly represses MICU1 expression in embryonic stem/progenitor cells, leading to suppressed mitochondrial Ca2+ uptake; experimental restoration of MICU1 in hESCs/hiPSCs re-established periodic cytosolic Ca2+ oscillations and promoted cellular differentiation and maturation.\",\n      \"method\": \"hESC/hiPSC and neonatal myocyte models, MICU1 expression analysis, FOXD1 overexpression/knockdown, Ca2+ imaging, bioenergetics assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct repression established by gain/loss-of-function with defined molecular target (MICU1) and functional consequence (Ca2+ dynamics, differentiation), multiple cell models\",\n      \"pmids\": [\"30158529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In developing hypothalamus, Foxd1 acts in neuroepithelial/neural progenitor cells to allow sustained expression of molecular markers of the suprachiasmatic, paraventricular, and periventricular hypothalamic nuclei; Foxd1-deficient mice show progressive loss of these markers after neurogenesis is complete, indicating Foxd1 is required for terminal differentiation of anterior hypothalamic neuronal subtypes.\",\n      \"method\": \"Foxd1 knockout mouse, immunostaining, in situ hybridization for hypothalamic markers (Six3, Vax1, neuropeptides)\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO with spatiotemporally defined molecular phenotype, single lab\",\n      \"pmids\": [\"29679559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In Xenopus, FoxD1 acts downstream of BMP antagonism to induce dorsal mesoderm (muscle and notochord) and is sensitive to local Wnt and BMP signaling; in the presence of Wnt or BMP activity FoxD1 induces posterior neural tissue, but when BMP and Wnt are repressed it induces anterior neural tissue, demonstrating context-dependent transcription factor activity.\",\n      \"method\": \"Antisense morpholino knockdown in Xenopus laevis, misexpression, epistasis with Wnt and BMP pathway manipulations\",\n      \"journal\": \"The International journal of developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — morpholino KD with epistasis, multiple signaling contexts tested, single lab, Xenopus model\",\n      \"pmids\": [\"28621426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FOXD1 transactivates galectin-3 (Gal-3) by directly binding to the Gal-3 promoter in lung cancer cells; ERK1/2 interacts with FOXD1 in the cytosol and translocates it into the nucleus to activate Gal-3. Gal-3 in turn upregulates FOXD1 via ETS-1/integrin-β1 signaling, forming a positive regulatory feedback loop that promotes lung cancer aggressiveness.\",\n      \"method\": \"Microarray, FOXD1 OE/KD in lung cancer cells, ChIP (FOXD1 binding to Gal-3 promoter), co-immunoprecipitation (ERK1/2-FOXD1), rescue experiments, xenograft\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus Co-IP plus functional rescue with multiple orthogonal methods in one study\",\n      \"pmids\": [\"31795213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FOXD1 suppresses proliferation of ovarian cancer cells and induces G1 arrest in a p53-independent manner by promoting p21 expression; chromatin immunoprecipitation and dual-luciferase reporter assays established FOXD1 as a direct transcriptional activator of p21.\",\n      \"method\": \"Lentiviral FOXD1 expression, ChIP, dual-luciferase reporter assay, flow cytometry, xenograft\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay establish direct transcriptional regulation of p21, single lab\",\n      \"pmids\": [\"29620165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FOXD1 promotes melanoma invasion and migration via indirect regulation of RAC1B (a tumor-specific Rac1 isoform) and MMP9; knockdown of RAC1B abrogates the enhanced invasiveness induced by FOXD1 overexpression, and FOXD1 regulates RAC1B through alternative splicing.\",\n      \"method\": \"FOXD1 KD/OE in melanoma cells, gene expression profiling, functional invasion/migration assays in vitro and in vivo, RAC1B rescue experiments\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — KD/OE with rescue, gene expression profiling, identified pathway (RAC1B alternative splicing), single lab\",\n      \"pmids\": [\"30110134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"YAP cooperates with TEAD to activate transcription of FOXD1; CRISPR/Cas9 KO of YAP in hMSCs reduces FOXD1 expression and causes premature cellular senescence, whereas overexpression of either YAP or FOXD1 rejuvenates aged hMSCs, establishing a YAP-TEAD-FOXD1 axis that controls senescence.\",\n      \"method\": \"CRISPR/Cas9 KO, lentiviral overexpression, ChIP (YAP/TEAD binding), senescence assays, intra-articular lentiviral delivery in mouse OA model\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO plus ChIP plus in vivo rescue, multiple orthogonal methods establishing direct transcriptional regulation\",\n      \"pmids\": [\"30933975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCL5 promotes angiogenesis via CXCR2-dependent activation of the AKT/NF-κB pathway, which upregulates FOXD1, which in turn drives VEGF-A expression; silencing FOXD1 attenuates HUVEC tube formation, proliferation, and migration stimulated by rhCXCL5.\",\n      \"method\": \"shFOXD1/shCXCR2 lentiviral stable knockdown in HUVECs, tube formation assay, AKT/NF-κB pathway inhibitors, in vivo Matrigel plug, xenograft\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — stable KD with pharmacological pathway inhibition and in vivo validation, single lab\",\n      \"pmids\": [\"30792394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-92a-1-5p targets FOXD1 (and FOXJ1) to activate CDX2 and downstream intestinal markers in bile-acids-induced gastric intestinal metaplasia via the NF-κB pathway; bile acids upregulate miR-92a-1-5p, suppressing FOXD1 and activating the miR-92a-1-5p/FOXD1/NF-κB/CDX2 axis.\",\n      \"method\": \"miRNA/mRNA microarray, miRNA mimic/inhibitor transfection, luciferase reporter assay (miR-92a-1-5p → FOXD1 3'-UTR), immunohistochemistry in IM tissue microarrays\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter plus functional cell assays with clinical tissue validation, single lab\",\n      \"pmids\": [\"30635407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FOXD1 directly promotes SLC2A1 (GLUT1) transcription and also inhibits GLUT1 mRNA degradation through the RNA-induced silencing complex, thereby enhancing aerobic glycolysis and promoting pancreatic cancer cell proliferation, invasion, and metastasis.\",\n      \"method\": \"FOXD1 OE/KD in pancreatic cancer cells, luciferase reporter (SLC2A1 promoter), RISC assay, in vitro and in vivo functional assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dual mechanism (transcription + RISC) established by reporter and RISC assays, single lab\",\n      \"pmids\": [\"36057597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FOXD1 repression in oral cancer cells downregulates G3BP2 (a negative regulator of p53), as determined by luciferase-based promoter assay establishing G3BP2 as a direct FOXD1 transcriptional target; FOXD1 KD promotes TXNIP expression (downstream of IFN signaling and a p53 activator) and enhances radiosensitivity.\",\n      \"method\": \"FOXD1 KD, differential gene expression analysis, luciferase promoter reporter assay for G3BP2, GSEA, luciferase reporter for IFN/p53 pathways\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter reporter establishes G3BP2 as FOXD1 target, single lab\",\n      \"pmids\": [\"32967107\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"METTL3 (m6A methyltransferase) mediates m6A modification of foxd1 mRNA; foxd1 mRNA levels and its methylation levels are elevated in renal ischemia-reperfusion injury and hypoxia/reoxygenation models, and METTL3 inhibition reduces both m6A and foxd1 mRNA, decreasing apoptosis.\",\n      \"method\": \"MeRIP sequencing, MeRIP-qRT-PCR, METTL3 inhibition in NRK-52E cells, rat IRI model\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MeRIP-seq identifies m6A modification of foxd1 mRNA by METTL3 with functional inhibition validation, single lab\",\n      \"pmids\": [\"32954854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FOXD1 directly binds to the SNAI2 promoter and activates its transcription, thereby promoting EMT and cell stemness in oral squamous cell carcinoma; elevated SNAI2 mediates the downstream effects on EMT markers and sphere formation.\",\n      \"method\": \"ChIP (FOXD1 binding to SNAI2 promoter), luciferase reporter assay, FOXD1 KD/OE, in vivo xenograft\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay establish direct transcriptional regulation of SNAI2, single lab\",\n      \"pmids\": [\"34348789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FOXD1 regulates the cell cycle in clear cell renal cell carcinoma (ccRCC) by controlling histone H3 phosphorylation at the G2/M transition; FOXD1 knockout in 786-O cells causes extended G2/M phase, deficient phospho-histone H3, increased DNA damage, and reduced tumor formation in xenografts, with downstream MICU1 as a co-regulated metabolic target.\",\n      \"method\": \"CRISPR/Cas9 FOXD1 knockout in 786-O cells, flow cytometry cell cycle analysis, immunoblotting for phospho-H3, γH2AX/TUNEL for DNA damage, Seahorse metabolic assay, xenograft\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with multiple orthogonal functional readouts (cell cycle, histone phosphorylation, DNA damage, metabolism, in vivo), single lab\",\n      \"pmids\": [\"33761914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"USP21 is a deubiquitinase for FOXD1 in mesenchymal glioblastoma stem cells: USP21 directly interacts with FOXD1 and reverses its K48-linked polyubiquitination, preventing proteasomal degradation. USP21 silencing enhances FOXD1 polyubiquitination and degradation, attenuating MES identity, effects rescued by FOXD1 reintroduction.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay (K48 linkage), USP21 knockdown with FOXD1 rescue, disulfiram (USP21 inhibitor) in vivo GBM xenograft\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP plus ubiquitination assay plus genetic rescue plus in vivo pharmacology, multiple orthogonal methods establishing the deubiquitinase–substrate relationship\",\n      \"pmids\": [\"35974001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOXD1 promotes CTC formation and breast cancer metastasis by directly inducing RalA expression (binding to the RalA promoter via ChIP-seq/CUT&Tag-seq); RalA then forms a complex with ANXA2 and Src, promoting ANXA2 Tyr23 phosphorylation and ERK1/2 activation.\",\n      \"method\": \"ChIP-seq, CUT&Tag-seq, luciferase reporter, GST-pulldown, co-immunoprecipitation, phosphorylation assays, in vitro and in vivo CTC/metastasis models, ERK1/2 inhibitor treatment\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP-seq plus CUT&Tag plus pulldown plus Co-IP plus in vivo rescue, multiple orthogonal methods establishing direct target and complex\",\n      \"pmids\": [\"36229838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In Sertoli cells, FOXD1 regulates testis development and function: FOXD1 knockdown in chicken Sertoli cells decreases AMH, SOX9, and RIα (PKA regulatory subunit) expression and increases androgen receptor expression, with DMRT1 unchanged, placing FOXD1 upstream of SOX9 in the Sertoli cell gene program.\",\n      \"method\": \"RNA interference in chicken Sertoli cells, qRT-PCR, immunohistochemistry, immunofluorescence for cell-type markers\",\n      \"journal\": \"Reproduction, fertility, and development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — RNAi with multiple molecular readouts in primary cells, single lab, avian model\",\n      \"pmids\": [\"30641031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOXD1 directly binds to the CTGF promoter and activates its transcription in melanoma cells, promoting dedifferentiation and resistance to BRAF inhibitor vemurafenib; CTGF knockdown increases BRAFi sensitivity similarly to FOXD1 KD, and recombinant CTGF restores resistance to FOXD1-KD cells.\",\n      \"method\": \"ChIP, luciferase reporter assay, FOXD1 KD/OE, CTGF KD, recombinant CTGF rescue, vemurafenib sensitivity assays\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter plus rescue experiments, single lab\",\n      \"pmids\": [\"33837564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FOXD1 directly interacts with β-catenin and promotes its nuclear translocation, activating downstream Wnt target genes (LGR5, Sox2), thereby increasing CRC cell stemness and chemoresistance; the β-catenin inhibitor XAV-939 blocks FOXD1-driven stemness.\",\n      \"method\": \"Co-immunoprecipitation (FOXD1–β-catenin), β-catenin nuclear fractionation, XAV-939 pharmacological rescue, stemness assays, xenograft limiting dilution\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishing direct interaction, nuclear fractionation, pharmacological rescue, single lab\",\n      \"pmids\": [\"37203394\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FOXD1 binds to the p21 promoter and inhibits its transcription, thereby blocking the CDK2/Rb signaling pathway and preventing senescence while accelerating proliferation of HNSCC cells; miR-30e-5p suppresses FOXD1 translation by targeting its 3'-UTR.\",\n      \"method\": \"ChIP (FOXD1 binding to p21 promoter), luciferase reporter, CDK2 inhibitor rescue, FOXD1 KD/OE, flow cytometry for senescence, miRNA target validation\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter plus CDK2 inhibitor rescue, single lab\",\n      \"pmids\": [\"37563111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRIM21 mediates K48-linked polyubiquitination of FOXD1 in hyperglycaemic conditions, leading to its proteasomal degradation; reduced FOXD1 decreases BCL-2 transcription (FOXD1 is a direct transcriptional activator of BCL-2), driving apoptosis in retinal and renal tissues. Tartary buckwheat flavonoids reverse FOXD1 protein downregulation.\",\n      \"method\": \"Ubiquitination assay (K48-linkage), proteasome inhibition, FOXD1 promoter reporter for BCL-2, FOXD1 KD/OE, diabetic mouse model tissue analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ubiquitination assay plus reporter assay plus in vivo model, single lab\",\n      \"pmids\": [\"38092733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FOXD1 promotes vasculogenic mimicry in glioma via transcriptional activation of DKK1 (direct promoter activation confirmed); upstream, SUMOylated RALY (facilitated by UBA2) increases FOXD1 mRNA stability.\",\n      \"method\": \"FOXD1 promoter-luciferase assay for DKK1, SUMOylation assay (SUMO1 conjugation), RALY stability assay, FOXD1 KD, in vivo glioma xenograft\",\n      \"journal\": \"Cell biology and toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter for DKK1 plus SUMOylation assay, single lab\",\n      \"pmids\": [\"37906341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FOXD1 directly binds to the KIFC1 promoter and activates its transcription (ChIP and dual-luciferase), upregulating the glycolysis pathway and conferring cisplatin resistance in breast cancer cells; FOXD1 positively regulates ANXA4 expression via KIFC1.\",\n      \"method\": \"ChIP, dual-luciferase reporter assay, FOXD1 OE/KD, KIFC1 KD/OE, ECAR/OCR metabolic assays, in vivo xenograft\",\n      \"journal\": \"Reproductive biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay plus metabolic assays, single lab\",\n      \"pmids\": [\"39541848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FOXD1 directly regulates IL-6 transcription in melanoma cells; FOXD1-induced IL-6 is pivotal for MDSC induction and immunosuppressive microenvironment formation. Blocking IL-6 reverses MDSC-associated immunosuppression driven by FOXD1 overexpression. In vivo, FOXD1-OE tumors contained more PD-L1+ MDSCs.\",\n      \"method\": \"FOXD1 OE/KD in melanoma cells, IL-6 ELISA, MDSC functional assay (arginase activity, T-cell suppression), IL-6 neutralization, flow cytometry, in vivo xenograft\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional rescue with IL-6 blockade plus in vivo validation, single lab, mechanism of IL-6 as direct transcriptional target suggested but full ChIP data not explicitly described in abstract\",\n      \"pmids\": [\"40210238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NAT10 stabilizes FOXD1 mRNA through ac4C (N4-acetylcytidine) modification; FOXD1 in turn acts as a transcriptional activator of NAT10 in NPC cells (confirmed by ChIP and luciferase assay), forming a positive feedback loop that drives NPC progression.\",\n      \"method\": \"RIP, mRNA stability assay, ChIP (FOXD1 binding to NAT10 promoter), luciferase reporter, FOXD1/NAT10 KD/OE, xenograft\",\n      \"journal\": \"Hereditas\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter plus RIP-mRNA stability, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"40999468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ALG3 directly interacts with FOXD1 and induces N-glycosylation at Asn176, which increases FOXD1 protein stability and promotes its nuclear localization; nuclear FOXD1 then transcriptionally activates BNIP3 to promote mitophagy and gemcitabine resistance in NPC cells.\",\n      \"method\": \"Co-IP (ALG3–FOXD1 interaction), N-glycosylation site mapping (Asn176), nuclear fractionation, ChIP/luciferase for BNIP3 promoter, mitophagy assay, drug resistance assay, xenograft\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — Co-IP plus PTM site identification plus nuclear localization plus direct promoter assay plus in vivo, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"40083705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FOXD1 mutations (p.His267Tyr and p.Arg57del) lead to disturbances in FOXD1 transcriptional activity on the C3 and PlGF gene promoters, functionally linking FOXD1 to RPL, RIF, IUGR, and preeclampsia pathogenesis via regulation of implantation/placental genes.\",\n      \"method\": \"FOXD1 gene sequencing in patients, in vitro gene reporter assays with mutant FOXD1 constructs on C3 and PlGF promoters\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay with patient-derived mutants directly tests transcriptional activity, single lab\",\n      \"pmids\": [\"31395028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXD1 sequence variants identified in RSA patients lead to perturbations in FOXD1 transactivation properties on promoters of implantation/placentation genes in vitro, implicating FOXD1 functional mutations in mammalian implantation processes.\",\n      \"method\": \"FOXD1 sequencing in RSA patients and controls, in vitro reporter transactivation assays with FOXD1 mutant constructs\",\n      \"journal\": \"Open biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay with disease-associated mutants, single lab\",\n      \"pmids\": [\"27805902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FOXD1 directly represses B4GALNT2 transcription in colorectal cancer cells; deletion experiments of putative FOXD1 binding sites in the ~2800 bp upstream B4GALNT2 promoter-luciferase construct confirmed regulatory binding, and FOXD1 knockdown in SW948 cells stimulates B4GALNT2 expression.\",\n      \"method\": \"Luciferase reporter with FOXD1 binding site deletions, transient transfection, FOXD1 KD\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — deletion reporter assay plus KD validation, single lab\",\n      \"pmids\": [\"39805916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FOXD1 directly activates ANXA3 transcription by binding to its promoter (validated by dual-luciferase reporter and ChIP), promoting ANXA4 expression via ANXA3–ANXA4 protein interaction (co-IP), thereby conferring cisplatin resistance in lung cancer cells.\",\n      \"method\": \"ChIP, dual-luciferase reporter (FOXD1 binding to ANXA3 promoter), co-IP (ANXA3–ANXA4), immunofluorescence, FOXD1/ANXA3 KD rescue experiments, xenograft\",\n      \"journal\": \"Naunyn-Schmiedeberg's archives of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter plus Co-IP, single lab\",\n      \"pmids\": [\"40095055\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FOXD1 is a forkhead/winged-helix transcription factor that functions primarily as a context-dependent transcriptional activator or repressor of a broad set of target genes (including PlGF, ALDH1A3, MICU1, SNAI2, Gal-3, RalA, GLUT1/SLC2A1, BCL-2, p21, BNIP3, KIFC1, DKK1, G3BP2, ANXA3, NAT10, and decorin/DCN); its activity is regulated upstream by YAP-TEAD, Sonic Hedgehog-GLI, Ets-1, WT-1/p53, and AKT/PKB signaling, and its protein stability is controlled post-translationally by TRIM21-mediated K48-polyubiquitination (counteracted by the deubiquitinase USP21) and by ALG3-mediated N-glycosylation at Asn176 that stabilizes it and promotes nuclear localization; in development, FOXD1 is essential for kidney stromal niche function, nephron progenitor differentiation, temporal retinal specification, optic chiasm formation, hypothalamic neuronal differentiation, and cell reprogramming to pluripotency, while in cancer it broadly promotes proliferation, EMT, stemness, angiogenesis, metabolic reprogramming (aerobic glycolysis), and therapy resistance across multiple tumor types.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FOXD1 is a forkhead/winged-helix transcription factor that governs cell-fate decisions during development and is broadly co-opted in cancer to drive proliferation, stemness, and therapy resistance [#0, #11]. It can act as a transcriptional activator or repressor depending on context, with its repressor function mapped to a dedicated repressor domain [#6]. In renal and ocular development it is essential: it directly binds the PlGF promoter to support ureteric bud branching [#0], represses decorin to permit BMP/SMAD-dependent nephron progenitor differentiation [#8], marks the stromal lineage that gives rise to erythropoietin-producing interstitial cells [#12], and is required in ventrotemporal retina to specify ipsilateral projections through Zic2/EphB1 and EphA6 [#4, #7]. Beyond the kidney and eye, FOXD1 patterns hypothalamic neuronal differentiation [#16] and is a mid-stage mediator of reprogramming to pluripotency [#9]. In tumors it directly transactivates targets that promote EMT and stemness (SNAI2), metabolic reprogramming toward aerobic glycolysis (SLC2A1/GLUT1, KIFC1), metastatic signaling (RalA), angiogenesis, and drug resistance (CTGF, BNIP3, ANXA3) [#27, #24, #30, #11, #40]. FOXD1 expression and activity are set by multiple upstream inputs including YAP-TEAD, Sonic Hedgehog, Ets-1, and AKT signaling [#21, #14, #1, #3], while its protein abundance is controlled post-translationally by TRIM21-mediated K48-polyubiquitination opposed by the deubiquitinase USP21, and by ALG3-mediated N-glycosylation at Asn176 that stabilizes the protein and promotes its nuclear localization [#35, #29, #40]. Patient-derived FOXD1 coding variants perturb its transactivation of implantation/placentation genes such as C3 and PlGF, linking FOXD1 dysfunction to recurrent pregnancy loss and related disorders [#41, #42].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that FOXD1 expression is itself a regulated node, placing it downstream of the developmental/tumor-suppressor transcription factors WT-1 and p53.\",\n      \"evidence\": \"Promoter-luciferase deletion mapping in kidney-derived cell lines with WT-1, mutant and wild-type p53\",\n      \"pmids\": [\"8702877\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct protein-DNA binding confirmed for WT-1 element\", \"Physiological relevance in vivo not tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified Ets-1 as a direct upstream activator of the FOXD1 promoter, defining a second transcriptional input controlling FOXD1 levels.\",\n      \"evidence\": \"Reporter assays, in vitro DNase footprinting with recombinant Ets-1, and site-directed mutagenesis in HEK293\",\n      \"pmids\": [\"9867825\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular context of Ets-1 regulation not defined\", \"Does not address FOXD1 target genes\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed FOXD1 integrates AKT/PKB and cAMP hormonal signals to activate the PKA RI-alpha 1b promoter, giving the first activity-mechanism placement of FOXD1 in a signaling circuit.\",\n      \"evidence\": \"Promoter deletion mapping, EMSA, and cotransfection with dominant-negative FOXD1 in adipocytes and Sertoli cells\",\n      \"pmids\": [\"11943768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation of FOXD1 by AKT not shown\", \"In vivo relevance untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined the first physiologically validated direct target of FOXD1, linking renal stromal FOXD1 to ureteric bud branching via PlGF.\",\n      \"evidence\": \"Inducible expression plus microarray, promoter binding, BF-2 null mouse, and kidney organ culture\",\n      \"pmids\": [\"13678594\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other stromal targets not enumerated\", \"Mechanism of FOXD1 activation in stroma not addressed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Established FOXD1 as a domain-encoded transcriptional repressor controlling temporal retinal identity, clarifying its activator/repressor duality.\",\n      \"evidence\": \"In ovo electroporation with chimeric repressor/activator domain-swap mutants in chick retina\",\n      \"pmids\": [\"19450575\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors mediating repression unidentified\", \"Does not address activator targets\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined EphA6 as a downstream effector of FOXD1 directing retinal axon targeting, extending the retinal program from identity to projection mechanics.\",\n      \"evidence\": \"Conditional mouse genetics with axon tracing and marker immunostaining\",\n      \"pmids\": [\"21490208\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect regulation of EphA6 not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed FOXD1 is a required mid-stage mediator of somatic cell reprogramming, connecting it to the pluripotency network through Dax1.\",\n      \"evidence\": \"Knockout, shRNA, fate-mapping reporter, and reprogramming transcriptome analysis\",\n      \"pmids\": [\"24496101\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct targets driving Dax1 not mapped\", \"Transient nature of FOXD1 expression mechanistically unexplained\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated by genetic epistasis that FOXD1 represses decorin to enable BMP/SMAD-dependent nephron progenitor differentiation, a defining renal developmental role.\",\n      \"evidence\": \"Foxd1/Dcn compound knockout rescue and BMP/SMAD pathway analysis in mouse\",\n      \"pmids\": [\"24284212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct promoter binding of FOXD1 to Dcn not shown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified the FOXD1 stromal lineage as the source of erythropoietin-producing interstitial cells, integrating FOXD1 lineage with PHD/HIF-2 oxygen sensing.\",\n      \"evidence\": \"Foxd1-Cre lineage tracing with EPO reporter and PHD compound mutants/pharmacology\",\n      \"pmids\": [\"27088801\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"FOXD1's direct transcriptional contribution to EPO regulation not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended FOXD1 from development into cancer, showing it sustains mesenchymal glioma stem cell identity via ALDH1A3, establishing the oncogenic stemness paradigm.\",\n      \"evidence\": \"shRNA, xenograft, transcriptional reporter, and cross-species RNAi epistasis\",\n      \"pmids\": [\"27569208\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect ALDH1A3 regulation not fully resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined FOXD1 as a direct repressor of MICU1 controlling mitochondrial Ca2+ uptake and differentiation, linking FOXD1 to metabolic/Ca2+ control of stemness.\",\n      \"evidence\": \"Gain/loss-of-function in hESC/hiPSC and myocytes with Ca2+ imaging and bioenergetics\",\n      \"pmids\": [\"30158529\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct promoter binding evidence limited\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed Sonic Hedgehog drives FOXD1 to repress Cdkn1c (p57), defining a Shh-FOXD1-Cdkn1c mitogenic circuit linking upstream morphogen signaling to proliferation.\",\n      \"evidence\": \"MEF knockout/overexpression, CDK pharmacology, and Cdkn1c Fox-enhancer reporter\",\n      \"pmids\": [\"29284139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of Shh-driven FOXD1 transcription not detailed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Placed FOXD1 downstream of YAP-TEAD in controlling cellular senescence, defining an anti-senescence/rejuvenation axis.\",\n      \"evidence\": \"CRISPR KO, ChIP for YAP/TEAD binding, senescence assays, and in vivo OA model\",\n      \"pmids\": [\"30933975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"FOXD1 senescence-suppressing targets in this context not fully mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed a Gal-3/ERK1/2/FOXD1 feedback loop in which cytosolic ERK1/2 binds FOXD1 and shuttles it into the nucleus, providing the first cytoplasmic-to-nuclear control mechanism for FOXD1.\",\n      \"evidence\": \"Microarray, ChIP, ERK1/2-FOXD1 Co-IP, rescue, and xenograft in lung cancer\",\n      \"pmids\": [\"31795213\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation sites mediating ERK1/2 interaction not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established post-translational control of FOXD1 abundance through the USP21 deubiquitinase opposing K48-polyubiquitination, explaining stabilization in mesenchymal GBM.\",\n      \"evidence\": \"Co-IP, K48 ubiquitination assay, USP21 knockdown with FOXD1 rescue, and disulfiram in vivo\",\n      \"pmids\": [\"35974001\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The E3 ligase opposed by USP21 not identified in this study\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined FOXD1-RalA as a direct metastatic axis, with RalA assembling an ANXA2-Src complex driving ERK signaling and circulating tumor cell formation.\",\n      \"evidence\": \"ChIP-seq, CUT&Tag, GST-pulldown, Co-IP, and in vivo CTC/metastasis models in breast cancer\",\n      \"pmids\": [\"36229838\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of the RalA axis across tumor types untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected FOXD1 to cell-cycle execution at G2/M and genome stability via control of histone H3 phosphorylation in ccRCC.\",\n      \"evidence\": \"CRISPR knockout in 786-O with cell-cycle, phospho-H3, DNA-damage, metabolic, and xenograft readouts\",\n      \"pmids\": [\"33761914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mechanism linking FOXD1 to histone H3 phosphorylation unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified ALG3-mediated N-glycosylation at Asn176 as a stabilizing modification that promotes FOXD1 nuclear localization and BNIP3-driven mitophagy/drug resistance, adding glycosylation to the FOXD1 regulatory repertoire.\",\n      \"evidence\": \"Co-IP, glycosylation site mapping, nuclear fractionation, ChIP/luciferase for BNIP3, and xenograft in NPC\",\n      \"pmids\": [\"40083705\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether glycosylation alters DNA-binding affinity not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked FOXD1 coding variants to human reproductive pathology by showing they impair transactivation of implantation/placentation genes.\",\n      \"evidence\": \"Patient sequencing plus reporter transactivation assays with mutant FOXD1 on C3 and PlGF promoters\",\n      \"pmids\": [\"31395028\", \"27805902\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causality vs association at population scale not established\", \"In vivo placental phenotype of variants untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how FOXD1 selects between activator and repressor modes at individual loci and which cofactors and chromatin contexts dictate its divergent developmental versus oncogenic target programs.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unifying structural/cofactor model for FOXD1 activator vs repressor switching\", \"Genome-wide direct target maps across tissues sparse\", \"Integration of the multiple PTM inputs (ubiquitination, glycosylation, ERK shuttling) into one regulatory logic undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 6, 8, 14, 15, 18, 19, 24, 27, 30, 35, 40]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 18, 27, 30, 37, 43, 44]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [18, 33, 40]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [18, 33]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 8, 14, 15, 27, 30]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 7, 8, 12, 16, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 24, 30, 32, 41]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [29, 35, 40]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"USP21\", \"TRIM21\", \"ALG3\", \"ERK1/2\", \"beta-catenin\", \"YAP\", \"TEAD\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}